US20150306375A1 - Implantable extravascular electrical stimulation lead having improved sensing and pacing capability - Google Patents
Implantable extravascular electrical stimulation lead having improved sensing and pacing capability Download PDFInfo
- Publication number
- US20150306375A1 US20150306375A1 US14/519,436 US201414519436A US2015306375A1 US 20150306375 A1 US20150306375 A1 US 20150306375A1 US 201414519436 A US201414519436 A US 201414519436A US 2015306375 A1 US2015306375 A1 US 2015306375A1
- Authority
- US
- United States
- Prior art keywords
- segment
- lead
- electrode
- defibrillation
- pace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3918—Heart defibrillators characterised by shock pathway, e.g. by electrode configuration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0504—Subcutaneous electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
- A61N1/3962—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
Definitions
- the present application relates to electrical stimulation leads and, more particularly, electrical stimulation leads with improved sensing and/or pacing capability for use in extravascular applications.
- VF ventricular fibrillation
- SCD sudden cardiac death
- An ICD system includes an ICD, which is a battery powered electrical stimulation device, that may include an electrical housing electrode (sometimes referred to as a can electrode), that is coupled to one or more electrical stimulation leads.
- the electrical stimulation leads may be placed within the heart, within vasculature near the heart (e.g., within the coronary sinus), attached to the outside surface of the heart (e.g., in the pericardium or epicardium), or implanted subcutaneously above the ribcage/sternum. If an arrhythmia is detected, the ICD may generate and deliver a pulse (e.g., cardioversion or defibrillation shock) via the electrical stimulation leads to shock the heart and restore its normal rhythm.
- a pulse e.g., cardioversion or defibrillation shock
- Subcutaneously implanted electrical stimulation leads or substernally implanted electrical stimulation leads do not intimately contact the heart, but instead reside in a plane of tissue or muscle between the skin and sternum for subcutaneous, or reside in a plane of tissue or muscle between the sternum and the heart for substernal. Due to the distance between the heart and electrodes of the electrical stimulation leads, to achieve improved pacing, sensing, and/or defibrillation, the pace/sense electrodes and the defibrillation coil electrode should be positioned in the plane of tissue such that the electrodes are located directly above or proximate the ventricular surface of the cardiac silhouette.
- the electrode(s) used to deliver pacing pulses should be positioned in a vector over substantially the center of the chamber to be paced to produce the lowest pacing capture thresholds for pacing.
- the electrode(s) used to sense cardiac electrical activity of the heart should be positioned over substantially the center the chamber to be sensed to obtain the best sensed signal.
- the defibrillation coil electrode it is preferred to have the defibrillation coil electrode positioned over substantially the center the chamber to be shocked.
- this disclosure is directed to an implantable medical electrical lead comprising an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance, a first electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment and the second segment of the defibrillation electrode, and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
- this disclosure is directed to an implantable medical electrical lead comprising an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by approximately 1-3 centimeters (cm), and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
- this disclosure is directed to an extravascular implantable cardioverter-defibrillator system comprising an implantable cardioverter-device (ICD) that includes a therapy module configured to generate and deliver electrical stimulation therapy and an implantable medical electrical lead electrically coupled to the therapy module.
- the lead includes an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance, and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
- FIGS. 1A and 1B are conceptual drawings illustrating various views of a patient implanted with an example extravascular implantable cardioverter-defibrillator (ICD) system.
- ICD extravascular implantable cardioverter-defibrillator
- FIG. 2 is a drawing illustrating a distal portion of an example implantable medical electrical lead.
- FIGS. 3A-3C are conceptual drawings illustrating various views of a patient implanted with an example extravascular ICD system in which a distal portion of the lead is implanted substernally.
- FIG. 4 is a block diagram illustrating components of an example ICD.
- FIGS. 1A and 1B are conceptual diagrams of an extravascular implantable cardioverter-defibrillator (ICD) system 10 subcutaneously implanted within a patient 12 .
- FIG. 1A is a front view of ICD system 10 implanted within patient 12 .
- FIG. 1B is a side view of ICD system 10 implanted within patient 12 .
- ICD system 10 includes an ICD 14 connected to a medical electrical lead 16 .
- FIGS. 1A and 1B are described in the context of an ICD system capable of providing defibrillation and/or cardioversion shocks and, in some instances, pacing pulses. However, the techniques of this disclosure may also be used in the context of other implantable medical devices configured to provide electrical stimulation pulses to stimulate other portions of the body of patient 12 .
- ICD 14 may include a housing that forms a hermetic seal that protects components of ICD 14 .
- the housing of ICD 14 may be formed of a conductive material, such as titanium or titanium alloy, that may function as a housing electrode (sometimes referred to as a can electrode).
- ICD 14 may also include a connector assembly (also referred to as a connector block or header) that includes electrical feedthroughs through which electrical connections are made between conductors of lead 16 and electronic components included within the housing of ICD 14 .
- housing may house one or more processors, memories, transmitters, receivers, sensors, sensing circuitry, therapy circuitry, power sources and other appropriate components.
- the housing is configured to be implanted in a patient, such as patient 12 .
- ICD 14 is implanted subcutaneously on the left side of patient 12 above the ribcage. ICD 14 may, in some instances, be implanted between the left posterior axillary line and the left anterior axillary line of patient 12 . ICD 14 may, however, be implanted at other subcutaneous locations on patient 12 as described later.
- Lead 16 includes an elongated lead body having a proximal end that includes a connector (not shown) configured to be connected to ICD 14 and a distal portion that includes electrodes 24 (formed by electrode segments 24 A and 24 B), 28 , 29 , and 30 .
- Lead 16 extends subcutaneously above the ribcage from ICD 14 toward a center of the torso of patient 12 , e.g., toward xiphoid process 20 of patient 12 .
- lead 16 bends or turns and extends superior subcutaneously above the ribcage and/or sternum, substantially parallel to sternum 22 .
- lead 16 may be implanted at other locations, such as over sternum 22 , offset to the right or left of sternum 22 , angled lateral from sternum 22 at either the proximal or distal end, or the like.
- the elongated lead body of lead 16 contains a plurality of elongated electrical conductors (not illustrated) that extend within the lead body from the connector at the proximal lead end to electrodes 24 , 28 , 29 , and 30 located along the distal portion of lead 16 .
- the elongated lead body may have a generally uniform shape along the length of the lead body. In one example, the elongated lead body may have a generally tubular or cylindrical shape along the length of the lead body.
- the elongated lead body may have a diameter of between 3 and 9 French (Fr) in some instances. However, lead bodies of less than 3 Fr and more than 9 Fr may also be utilized.
- the distal portion (or all of) the elongated lead body may have a flat, ribbon or paddle shape.
- the width across the flat portion of the flat, ribbon or paddle shape may be between 1 and 3.5 mm.
- Other lead body designs may be used without departing from the scope of this disclosure.
- the lead body of lead 16 may be formed from a non-conductive material, including silicone, polyurethane, fluoropolymers, mixtures thereof, and other appropriate materials, and shaped to form one or more lumens within which the one or more conductors extend.
- the techniques are not limited to such constructions.
- the one or more elongated electrical conductors contained within the lead body of lead 16 may engage with respective electrodes 24 , 28 , 29 , and 30 .
- each of electrodes 28 , 29 , and 30 are electrically coupled to a respective conductor within the lead body.
- Electrode segments 24 A and 24 B may be electrically coupled to separate conductors, but may be capable of being jumpered, tied or otherwise electrically connected such that segments 24 A and 24 B may together form an anode or cathode of a therapy vector. Alternatively, electrode segments 24 A and 24 B may be electrically coupled to the same conductor.
- the respective conductors may electrically couple to circuitry, such as a therapy module or a sensing module, of ICD 14 via connections in the connector assembly, including associated feedthroughs.
- the electrical conductors transmit therapy from a therapy module within ICD 14 to one or more of electrodes 24 (or one of segments 24 A and 24 B), 28 , 29 and 30 and transmit sensed electrical signals from one or more of electrodes 24 (or one of segments 24 A and 24 B), 28 , 29 and 30 to the sensing module within ICD 14 .
- Defibrillation electrode 24 is located toward the distal portion of defibrillation lead 16 , e.g., toward the portion of defibrillation lead 16 extending superior near sternum 22 .
- defibrillation electrode 24 is formed of a first electrode segment 24 A and a second electrode segment 24 B separated by a distance.
- first segment 24 A and second segment 24 B are each approximately 2-5 cm in length and the proximal end of segment 24 A is separated by approximately 1-3 cm from the distal end of segment 24 B.
- the first electrode segment 24 A and the second electrode segment 24 B of defibrillation electrode 24 may in one example be coil electrode segments.
- defibrillation electrode 24 may be a flat ribbon electrode, paddle electrode, braided or woven electrode, mesh electrode, directional electrode, patch electrode or other type of electrode that is segmented in the manner described herein. Moreover, in other examples, defibrillation electrode 24 may be constructed of more than two segments.
- a total length of defibrillation electrode 24 may vary depending on a number of variables. Defibrillation electrode 24 may, in one example, have a total length (e.g., length of the two segments combined) of between approximately 5-10 centimeters (cm). However, defibrillation electrode 24 may have a total length less than 5 cm and greater than 10 cm in other embodiments. In another example, defibrillation electrode 24 may have a total length of approximately 2-16 cm. In some instances, defibrillation segments 24 A and 24 B may be approximately the same length. In other instances, one of defibrillation segments 24 A and 24 B may be longer or shorter than the other one of the defibrillation segments 24 A and 24 B.
- Defibrillation lead 16 also includes electrodes 28 , 29 and 30 located along the distal portion of defibrillation lead 16 .
- electrodes 28 and 29 are located between defibrillation electrode segments 24 A and 24 B and electrode 30 is located distal of defibrillation electrode segment 24 A.
- Electrodes 28 and 29 are illustrated as ring electrodes and electrode 30 is illustrated as a hemispherical tip electrode.
- electrodes 28 , 29 , and 30 may comprise any of a number of different types of electrodes, including ring electrodes, short coil electrodes, paddle electrodes, hemispherical electrodes, directional electrodes, segmented electrodes, or the like.
- electrodes 28 and 29 may be formed of a conductive material that only extends around a portion of the circumference of the lead body, e.g., a half-ring electrode, quarter-ring electrode, or other partial-ring electrode.
- electrodes 28 and 29 may be formed of conductive material that extends around the entire circumference of the lead body, but may be partially coated with an insulating material to form the half-ring electrode, quarter-ring electrode, or other partial-ring electrode.
- electrode 30 may be formed into a partial-hemispherical electrode in a similar manner as described above with respect to ring electrodes 28 and 29 .
- one or more of electrodes 28 , 29 , and 30 may be segmented electrodes (e.g., half- or quarter-ring or hemispherical electrodes) with separate conductors connected to each of the segments or a single conductor with a multiplexor or other switch to switch between the segmented electrodes such that the segments may be used as individual electrodes.
- segmented electrodes e.g., half- or quarter-ring or hemispherical electrodes
- Electrodes 28 , 29 , and 30 of lead 16 may have substantially the same outer diameter as the lead body.
- electrodes 28 , 29 , and 30 may have surface areas between 1.6-150 mm 2 . Electrodes 28 and 30 may, in some instances, have relatively the same surface area or different surface areas.
- Electrodes 28 and 29 are spaced apart from one another along the length of the lead. The spacing between electrodes 28 and 29 may be dependent upon the configuration of lead 16 . In one example, electrodes 28 and 29 are spaced apart by less than 2 cm. In some instances, electrodes 28 and 29 may be spaced apart by less than 1 cm. In further instances, electrodes 28 and 29 may be spaced apart from one another by more than 2 cm. Electrode 30 is spaced apart from the distal end of defibrillation electrode segment 24 A by a distance, which may again be less than 2 cm. However, electrode 30 may be spaced apart from the distal end of defibrillation electrode segment 24 A by more than 2 cm.
- lead 16 may include less than three pace/sense electrodes or more than three pace/sense electrodes.
- the pace/sense electrodes may be located elsewhere along the length of lead 16 , e.g., distal to defibrillation electrode segment 24 A or proximal to defibrillation electrode segment 24 B, with one or more of the sense/pace electrodes being located between defibrillation electrode segments 24 A and 24 B.
- defibrillation electrode may be constructed of more than two segments, such as three segments with electrode 28 located between the proximal segment and middle segment and electrode 29 located between the middle segment and the distal segment.
- the pace/sense electrodes located substantially over the chamber of heart 26 that is being paced and/or sensed. For example, it is desirable to locate the pace/sense electrodes over a cardiac silhouette of the ventricle as observed via an anterior-posterior (AP) fluoroscopic view of heart 26 for sensing or pacing the ventricle.
- AP anterior-posterior
- the defibrillation electrode located substantially over the chamber of heart 26 to which the defibrillation or cardioversion shock is being applied, e.g., over a cardiac silhouette of the ventricle as observed via an AP fluoroscopic view of heart 26 .
- Leads designed in accordance with any of the techniques described herein can be implanted to achieve desirable electrode positioning for both defibrillation and pacing/sensing.
- lead 16 may be implanted such that electrodes 28 and 29 are substantially located over a cardiac silhouette of the ventricle as observed via an AP fluoroscopic view of heart 26 .
- lead 16 may be implanted such that one or both of a unipolar pacing/sensing vector from electrode 28 or 29 to a housing electrode of ICD 14 are substantially across the ventricles of heart 26 .
- the therapy vector may be viewed as a line that extends from a point on electrode 28 or 29 , e.g., center of electrode 28 or 29 , to a point on the housing electrode of ICD 14 , e.g., center of the housing electrode.
- the spacing between electrodes 28 and 29 as well as the placement of lead 16 may be such that a bipolar pacing vector between electrode 28 and electrode 29 is centered or otherwise located substantially over the ventricle.
- Electrode 30 may be located over the cardiac silhouette of the atrium or near the top of the cardiac silhouette of the atrium as observed via an AP fluoroscopic view. As such, electrode 30 may offer an alternate sensing vector and/or provide atrial pacing if needed or desired.
- defibrillation electrode segments 24 A and 24 B are substantially centered over the cardiac silhouette of the ventricle as observed via an AP fluoroscopic view of heart 26 .
- the therapy vector from defibrillation electrode segments 24 A and 24 B to the housing of ICD 14 is substantially across the ventricles of heart 26 .
- electrodes 24 , 28 , 29 , and/or 30 of lead 16 may be shaped, oriented, designed or otherwise configured to reduce extra-cardiac stimulation.
- electrodes 24 , 28 , 29 , and/or 30 of lead 16 may be shaped, oriented, designed, partially insulated or otherwise configured to focus, direct or point electrodes 24 , 28 , 29 , and/or 30 toward heart 26 . In this manner, pacing pulses delivered via lead 16 are directed toward heart 26 and not outward toward skeletal muscle.
- electrodes 24 , 28 , 29 , and/or 30 of lead 16 may be partially coated or masked with a polymer (e.g., polyurethane) or another coating material (e.g., tantalum pentoxide) on one side or in different regions so as to direct the pacing signal toward heart 26 and not outward toward skeletal muscle.
- a polymer e.g., polyurethane
- another coating material e.g., tantalum pentoxide
- the ring electrode may be partially coated with the polymer or other material to form a half-ring electrode, quarter-ring electrode, or other partial-ring electrode.
- ICD 14 may obtain sensed electrical signals corresponding with electrical activity of heart 26 via a combination of sensing vectors that include combinations of electrodes 28 , 29 , and/or 30 and the housing electrode of ICD 14 .
- ICD 14 may obtain electrical signals sensed using a sensing vector between any two of electrodes 28 , 29 and 30 or obtain electrical signals sensed using a sensing vector between any one of electrodes 28 , 29 , or 30 and the conductive housing electrode of ICD 14 .
- ICD 14 may even obtain sensed electrical signals using a sensing vector that includes one or both segments 24 A or 24 B of defibrillation electrode 24 in combination with electrodes 28 , 29 , and/or 30 , or the housing electrode of ICD 14 .
- ICD 14 analyzes the sensed electrical signals obtained from one or more of the sensing vectors of lead 16 to monitor for tachyarrhythmia, such as ventricular tachycardia (VT) or ventricular fibrillation (VF).
- ICD 14 may analyze the heart rate and/or morphology of the sensed electrical signals to monitor for tachyarrhythmia in accordance with any of a number of techniques known in the art.
- One example technique for detecting tachyarrhythmia is described in U.S. Pat. No.
- ICD 14 generates and delivers electrical stimulation therapy in response to detecting tachycardia (e.g., VT or VF). In response to detecting the tachycardia, ICD 14 may deliver one or more cardioversion or defibrillation shocks via defibrillation electrode 24 of lead 16 . ICD 14 may deliver the cardioversion or defibrillation shocks using either of the electrode segments 24 A and 24 B individually or together. ICD 14 may generate and deliver electrical stimulation therapy other than cardioversion or defibrillation shocks, including post-shock pacing using a therapy vector formed from one or more of electrodes 24 , 28 , 28 , 30 , and the housing electrode.
- tachycardia e.g., VT or VF
- ICD 14 may deliver one or more cardioversion or defibrillation shocks via defibrillation electrode 24 of lead 16 .
- ICD 14 may deliver the cardioversion or defibrillation shocks using either of the electrode segments 24 A
- ICD 14 and lead 16 may be implanted at other locations.
- ICD 14 may be implanted in a subcutaneous pocket in the right pectoral region.
- defibrillation lead 16 may extend subcutaneously from the device toward the manubrium of sternum 22 and bend or turn and extend inferior from the manubrium to the desired location.
- ICD 14 may be placed abdominally or intrathoracically.
- Lead 16 may be implanted in other extravascular locations as well. For instance, as described with respect to FIGS. 3A-3C , lead 16 may be implanted underneath the sternum/ribcage.
- system 10 is an ICD system that provides cardioversion/defibrillation and, in some instances, pacing therapy.
- these techniques may be applicable to other cardiac systems, including cardiac resynchronization therapy defibrillator (CRT-D) systems or other cardiac stimulation therapies, or combinations thereof.
- ICD 14 may be configured to provide electrical stimulation pulses to stimulate nerves, skeletal muscles, diaphragmatic muscles, e.g., for various neuro-cardiac applications and/or for sleep apnea or respiration therapy.
- defibrillation lead 16 may be placed further superior such that the defibrillation electrode 24 is placed substantially over the atrium of heart 26 to provide a shock or pulse to the atrium to terminate atrial fibrillation (AF).
- defibrillation lead 16 may include a second defibrillation electrode (e.g., second elongated coil electrode) near a proximal end of lead 16 or near a middle portion of lead 16 .
- FIG. 2 is a conceptual diagram illustrating a distal portion of another example implantable electrical lead 40 with improved pacing and/or sensing capability for use in non-vascular, extra-pericardial applications.
- Lead 40 can include one or more of the structure and/or functionality of lead 16 of FIGS. 1A and 1B (and vice versa). Repetitive description of like numbered elements described in other embodiments is omitted for sake of brevity. Lead 40 may be used in place of lead 16 in ICD system 10 of FIGS. 1A and 1B .
- Lead 40 conforms substantially with lead 16 of FIGS. 1A and 1B , but instead of having ring electrodes 28 and 29 located between defibrillation segments 24 A and 24 B, lead 40 includes a pace/sense coil electrode 42 between defibrillation segments 24 A and 24 B and a pace/sense ring electrode 44 proximal to defibrillation electrode segment 24 B. Such a configuration may increase the surface area located over the ventricles.
- the length of pace/sense coil electrode 42 may be dependent upon the spacing between defibrillation segments 24 A and 24 B.
- defibrillation segments 24 A and 24 B may each have lengths approximately equal to 4 cm and be spaced apart by a distance greater than 1 cm.
- the pace/sense coil electrode 42 may have a length of approximately 1 cm.
- ICD 14 may be configured to sense and deliver pacing and/or cardioversion/defibrillation using any combination of electrodes 24 , 30 , 42 , 44 , and the housing electrode.
- Lead 40 may be implanted such that electrode 42 and defibrillation electrode 24 is subtantially over the ventricular surface of the cardiac silhouette in the same manner as described above with respsect to FIGS. 1A and 1B .
- FIGS. 3A-3C are conceptual diagrams of patient 12 implanted with another example ICD system 110 .
- FIG. 3A is a front view of patient 12 implanted with ICD system 110 .
- FIG. 3B is a side view of patient 12 implanted with ICD system 110 .
- FIG. 3C is a transverse view of patient 12 with ICD system 110 .
- ICD system 110 can include one or more of the structure and/or functionality of system 10 of FIGS. 1A-1B (and vice versa).
- ICD system 110 of FIGS. 3A-3C is illustrated with lead 16 for purposes of illustration, but may be utilized with any of leads 16 or 40 or other similar lead. Repetitive description of like numbered elements described in other embodiments is omitted for sake of brevity.
- ICD system 110 conforms substantially to ICD system 10 of FIGS. 1A-1B , except defibrillation lead 16 of system 110 is implanted at least partially underneath sternum 22 of patient 12 .
- Lead 16 extends subcutaneously from ICD 14 toward xiphoid process 20 , and at a location near xiphoid process 20 bends or turns and extends superior underneath/below sternum 22 within anterior mediastinum 36 .
- Anterior mediastinum 36 may be viewed as being bounded laterally by pleurae 39 , posteriorly by pericardium 38 , and anteriorly by sternum 22 .
- anterior wall of anterior mediastinum 36 may also be formed by the transversus thoracis and one or more costal cartilages.
- Anterior mediastinum 36 includes a quantity of loose connective tissue (such as areolar tissue), some lymph vessels, lymph glands, substernal musculature (e.g., transverse thoracic muscle), branches of the internal thoracic artery, and the internal thoracic vein.
- the distal portion of lead 16 extends along the posterior side of sternum 22 substantially within the loose connective tissue and/or substernal musculature of anterior mediastinum 36 .
- a lead implanted such that the distal portion is substantially within anterior mediastinum 36 will be referred to herein as a substernal lead.
- electrical stimulation such as pacing, cardioversion or defibrillation
- lead 16 implanted substantially within anterior mediastinum 36 will be referred to herein as substernal electrical stimulation, substernal pacing, substernal cardioversion, or substernal defibrillation.
- the distal portion of lead 16 is described herein as being implanted substantially within anterior mediastinum 36 .
- points along the distal portion of lead 16 may extend out of anterior mediastinum 36 , but the majority of the distal portion is within anterior mediastinum 36 .
- the distal portion of lead 16 may be implanted in other non-vascular, extra-pericardial locations, including the gap, tissue, or other anatomical features around the perimeter of and adjacent to, but not attached to, the pericardium or other portion of heart 26 and not above sternum 22 or ribcage.
- lead 16 may be implanted anywhere within the “substernal space” defined by the undersurface between the sternum and/or ribcage and the body cavity but not including the pericardium or other portion of heart 26 .
- the substernal space may alternatively be referred to by the terms “retrosternal space” or “mediastinum” or “infrasternal” as is known to those skilled in the art and includes the anterior mediastinum 36 .
- the substernal space may also include the anatomical region described in Baudoin, Y. P., et al., entitled “The superior epigastric artery does not pass through Larrey's space (trigonum sternocostale).” Surg. Radiol. Anat. 25.3-4 (2003): 259-62 as Larrey's space.
- the distal portion of lead 16 may be implanted in the region around the outer surface of heart 26 , but not attached to heart 26 .
- the distal portion of lead 16 may be implanted substantially within anterior mediastinum 36 such that electrodes 28 and 29 are located near a ventricle of heart 26 .
- the pace/sense electrodes located substantially over the chamber of heart 26 that is being paced and/or sensed.
- lead 16 may be implanted within anterior mediastinum 36 such that 28 and 29 are located over a cardiac silhouette of one or both ventricles as observed via an AP fluoroscopic view of heart 26 .
- lead 16 may be implanted such that one or both of a unipolar pacing/sensing vector from electrode 28 or 29 to a housing electrode of ICD 14 are substantially across the ventricles of heart 26 .
- the spacing between electrodes 28 and 29 as well as the placement of lead 16 may be such that a bipolar pacing vector between electrode 28 and electrode 29 is centered or otherwise located over the ventricle.
- the defibrillation electrode located substantially over the chamber of heart 26 to which the defibrillation or cardioversion shock is being applied, e.g., over a cardiac silhouette of the ventricle as observed via an AP fluoroscopic view of heart 26 .
- the defibrillation electrode or the sense electrode it is only possible to position either the defibrillation electrode or the sense electrode over the relevant chamber, but not both.
- electrodes 28 and 29 located over the ventricle, but due to the layout of the electrodes on the lead 16 , defibrillation electrode segments 24 A and 24 B are also substantially centered over the cardiac silhouette of the ventricle as observed via an AP fluoroscopic view of heart 26 .
- lead 16 is designed to provide desirable electrode positioning for both defibrillation and pacing/sensing concurrently.
- lead 16 is located substantially centered under sternum 22 . In other instances, however, lead 16 may be implanted such that it is offset laterally from the center of sternum 22 . In some instances, lead 16 may extend laterally enough such that all or a portion of lead 16 is underneath/below the ribcage in addition to or instead of sternum 22 .
- Placing lead 16 in the substernal space may provide a number of advantages. For example, placing lead 16 in the substernal space may significantly reduce the amount of energy that needs to be delivered to defibrillate heart 26 .
- ICD 14 may generate and deliver cardioversion or defibrillation shocks having energies of less than 65 Joules (J), less than 60 J, between 35-60 J, and in some cases possibly less than 35 J.
- J Joules
- placing defibrillation lead 16 within the substernal space e.g., with the distal portion substantially within anterior mediastinum 36 , may result in reduced energy consumption and, in turn, smaller devices and/or devices having increased longevity.
- pacing such as anti-tachycadia pacing (ATP), post-shock pacing and, in some cases, bradycardia pacing
- ICD 14 may deliver one or more sequences of ATP in an attempt to terminate a detected VT without delivering a defibrillation shock.
- the ATP may be delivered via one or more therapy vectors of lead 16 , e.g., unipolar therapy vector, bipolar pacing vector or multipolar pacing vector, formed using electrodes 28 , 29 , or 30 , housing electrode of ICD 14 , and/or defibrillation electrode 24 or individual defibrillation electrode segments 24 A or 24 B. If the one or more sequences of ATP are not successful, it is determined that ATP is not desired (e.g., in the case of VF), or ICD 14 is not configured to deliver ATP, ICD 14 may deliver one or more cardioversion or defibrillation shocks via defibrillation electrode 24 of lead 16 .
- therapy vectors of lead 16 e.g., unipolar therapy vector, bipolar pacing vector or multipolar pacing vector, formed using electrodes 28 , 29 , or 30 , housing electrode of ICD 14 , and/or defibrillation electrode 24 or individual defibrillation electrode segments 24 A or
- ICD 14 may deliver the cardioversion or defibrillation shocks using either of the electrode segments 24 A and 24 B individually or together. ICD 14 may generate and deliver electrical stimulation therapy other than ATP, cardioversion or defibrillation shocks, including post-shock pacing, bradycardia pacing, or other electrical stimulation therapy using a therapy vector formed from one or more of electrodes 24 , 28 , 28 , 30 , and the housing electrode.
- FIG. 4 is a functional block diagram of an example configuration of electronic components of an example ICD 14 .
- ICD 14 includes a control module 60 , sensing module 62 , therapy module 64 , communication module 68 , and memory 70 .
- the electronic components may receive power from a power source 66 , which may be a rechargeable or non-rechargeable battery.
- ICD 14 may include more or fewer electronic components.
- the described modules may be implemented together on a common hardware component or separately as discrete but interoperable hardware or software components. Depiction of different features as modules is intended to highlight different functional aspects and does not necessarily imply that such modules must be realized by separate hardware or software components.
- FIG. 4 will be described in the context of ICD being coupled to lead 16 for exemplary purposes only. However, ICD 14 may be coupled to other leads, such as lead 40 described herein, and thus other electrodes, such as electrodes 42 and 44 .
- Sensing module 62 is electrically coupled to some or all of electrodes 24 (or separately to segments 24 A and/or 24 B), 28 , 29 , and 30 via the conductors of lead 16 and one or more electrical feedthroughs, or to the housing electrode via conductors internal to the housing of ICD 14 .
- Sensing module 62 is configured to obtain signals sensed via one or more combinations of electrodes 24 (or segments 24 A and/or 24 B), 28 , 29 , and 30 and the housing electrode of ICD 14 and process the obtained signals.
- sensing module 62 may be analog components, digital components or a combination thereof.
- Sensing module 62 may, for example, include one or more sense amplifiers, filters, rectifiers, threshold detectors, analog-to-digital converters (ADCs) or the like.
- Sensing module 62 may convert the sensed signals to digital form and provide the digital signals to control module 60 for processing or analysis.
- sensing module 62 may amplify signals from the sensing electrodes and convert the amplified signals to multi-bit digital signals by an ADC.
- Sensing module 62 may also compare processed signals to a threshold to detect the existence of atrial or ventricular depolarizations (e.g., P- or R-waves) and indicate the existence of the atrial depolarization (e.g., P-waves) or ventricular depolarizations (e.g., R-waves) to control module 60 .
- a threshold to detect the existence of atrial or ventricular depolarizations (e.g., P- or R-waves) and indicate the existence of the atrial depolarization (e.g., P-waves) or ventricular depolarizations (e.g., R-waves) to control module 60 .
- Control module 60 may process the signals from sensing module 62 to monitor electrical activity of heart 26 of patient 12 .
- Control module 60 may store signals obtained by sensing module 62 as well as any generated EGM waveforms, marker channel data or other data derived based on the sensed signals in memory 70 .
- Control module 60 may analyze the EGM waveforms and/or marker channel data to detect cardiac events (e.g., tachycardia).
- cardiac events e.g., tachycardia
- control module 60 may control therapy module 64 to deliver the desired therapy to treat the cardiac event, e.g., defibrillation shock, cardioversion shock, ATP, post-shock pacing, or bradycardia pacing.
- Therapy module 64 is configured to generate and deliver electrical stimulation therapy to heart 26 .
- Therapy module 64 may include one or more pulse generators, capacitors, and/or other components capable of generating and/or storing energy to deliver as pacing therapy, defibrillation therapy, cardioversion therapy, cardiac resynchronization therapy, other therapy or a combination of therapies.
- therapy module 64 may include a first set of components configured to provide pacing therapy and a second set of components configured to provide defibrillation therapy.
- therapy module 64 may utilize the same set of components to provide both pacing and defibrillation therapy.
- therapy module 64 may share some of the defibrillation and pacing therapy components while using other components solely for defibrillation or pacing.
- Control module 60 may control therapy module 64 to deliver the generated therapy to heart 26 via one or more combinations of electrodes 24 (or separately to segments 24 A and/or 24 B), 28 , 29 , and 30 of lead 16 and the housing electrode of ICD 14 according to one or more therapy programs, which may be stored in memory 70 .
- control module 60 controls therapy module 64 to generate electrical stimulation therapy with the amplitudes, pulse widths, timing, frequencies, electrode combinations or electrode configurations specified by a selected therapy program.
- Therapy module 64 may include a switch module to select which of the available electrodes are used to deliver the therapy.
- the switch module may include a switch array, switch matrix, multiplexer, or any other type of switching device suitable to selectively couple electrodes to therapy module 64 .
- Control module 60 may select the electrodes to function as therapy electrodes, or the therapy vector, via the switch module within therapy module 64 .
- control module 60 may be configured to selectively couple therapy module 64 to either one of segments 24 A or 24 B individually or couple to both of the segments 24 A and 24 B concurrently.
- the same switch module may be used by both therapy module 64 and sensing module 62 .
- each of sensing module 62 and therapy module 64 may have separate switch modules.
- control module 60 controls therapy module 64 to generate and deliver pacing pulses with any of a number of shapes, amplitudes, pulse widths, or other characteristic to capture heart 26 .
- the pacing pulses may be monophasic, biphasic, or multi-phasic (e.g., more than two phases).
- the pacing thresholds of heart 26 when delivering pacing pulses from the substernal space, e.g., from electrodes 28 , 29 , and/or 30 substantially within anterior mediastinum 36 may depend upon a number of factors, including location, type, size, orientation, and/or spacing of electrodes 28 , 29 , and 30 , location of ICD 14 relative to electrodes 28 , 29 , and 30 , physical abnormalities of heart 26 (e.g., pericardial adhesions or myocardial infarctions), or other factor(s).
- therapy module 64 may be configured to generate and deliver pacing pulses having larger amplitudes and/or pulse widths than conventionally required to obtain capture via leads implanted within the heart (e.g., transvenous leads) or leads attached directly to heart 26 .
- therapy module 64 may generate and deliver pacing pulses having amplitudes of less than or equal to 8 volts and pulse widths between 0.5-3.0 milliseconds.
- therapy module 64 may generate and deliver pacing pulses having amplitudes of between 5 and 10 volts and pulse widths between approximately 3.0 milliseconds and 10.0 milliseconds. In another example, therapy module 64 may generate and deliver pacing pulses having pulse widths between approximately 2.0 milliseconds and 8.0 milliseconds. In a further example, therapy module 64 may generate and deliver pacing pulses having pulse widths between approximately 0.5 milliseconds and 20.0 milliseconds. In another example, therapy module 64 may generate and deliver pacing pulses having pulse widths between approximately 1.5 milliseconds and 20.0 milliseconds.
- Pacing pulses having longer pulse durations than conventional transvenous pacing pulses may result in lower energy consumption.
- therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than two (2) milliseconds.
- therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of between greater than two (2) milliseconds and less than or equal to three (3) milliseconds.
- therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to three (3) milliseconds.
- therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to five (5) milliseconds.
- therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to ten (10) milliseconds. In a further example, therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths between approximately 3-10 milliseconds. In a further example, therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to fifteen (15) milliseconds. In yet another example, therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to twenty (20) milliseconds.
- ICD 14 may be configured to deliver pacing pulses having pulse amplitudes less than or equal to twenty (20) volts, deliver pacing pulses having pulse amplitudes less than or equal to ten (10) volts, deliver pacing pulses having pulse amplitudes less than or equal to five (5) volts, deliver pacing pulses having pulse amplitudes less than or equal to two and one-half (2.5) volts, deliver pacing pulses having pulse amplitudes less than or equal to one (1) volt.
- the pacing pulse amplitudes may be greater than 20 volts.
- the lower amplitudes require longer pacing widths as illustrated in the experimental results. Reducing the amplitude of pacing pulses delivered by ICD 14 reduces the likelihood of extra-cardiac stimulation and lower consumed energy of power source 66 .
- pacing amplitudes and pulse widths may vary.
- control module 60 controls therapy module 64 to generate cardioversion or defibrillation shocks having any of a number of waveform properties, including leading-edge voltage, tilt, delivered energy, pulse phases, and the like.
- Therapy module 64 may, for instance, generate monophasic, biphasic or multiphasic waveforms. Additionally, therapy module 64 may generate cardioversion or defibrillation waveforms having different amounts of energy.
- delivering cardioversion or defibrillation shocks from the substernal space may reduce the amount of energy that needs to be delivered to defibrillate heart 26 .
- therapy module 64 may generate and deliver cardioversion or defibrillation shocks having energies of less than 65 J, less than 60 J, between 40-50 J, between 35-60 J, and in some instances less than 35 J.
- ICD 14 may generate and deliver cardioversion or defibrillation shocks having energies around 65-80 J.
- Therapy module 64 may also generate defibrillation waveforms having different tilts.
- therapy module 64 may use a 65/65 tilt, a 50/50 tilt, or other combinations of tilt.
- the tilts on each phase of the biphasic or multiphasic waveforms may be the same in some instances, e.g., 65/65 tilt. However, in other instances, the tilts on each phase of the biphasic or multiphasic waveforms may be different, e.g., 65 tilt on the first phase and 55 tilt on the second phase.
- the example delivered energies, leading-edge voltages, phases, tilts, and the like are provided for example purposes only and should not be considered as limiting of the types of waveform properties that may be utilized to provide substernal defibrillation via defibrillation electrode 24 .
- Communication module 68 includes any suitable hardware, firmware, software or any combination thereof for communicating with another device, such as a clinician programmer, a patient monitoring device, or the like.
- communication module 68 may include appropriate modulation, demodulation, frequency conversion, filtering, and amplifier components for transmission and reception of data with the aid of antenna 72 .
- Antenna 72 may be located within connector block of ICD 14 or within housing ICD 14 .
- the various modules of ICD 14 may include any one or more processors, controllers, digital signal processors (DSPs), application specific integrated circuits (ASICs), field-programmable gate arrays (FPGAs), or equivalent discrete or integrated circuitry, including analog circuitry, digital circuitry, or logic circuitry.
- Memory 70 may include computer-readable instructions that, when executed by control module 60 or other component of ICD 14 , cause one or more components of ICD 14 to perform various functions attributed to those components in this disclosure.
- Memory 70 may include any volatile, non-volatile, magnetic, optical, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), static non-volatile RAM (SRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other non-transitory computer-readable storage media.
- RAM random access memory
- ROM read-only memory
- NVRAM non-volatile RAM
- SRAM static non-volatile RAM
- EEPROM electrically-erasable programmable ROM
- flash memory or any other non-transitory computer-readable storage media.
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
Implantable medical electrical leads having electrodes arranged such that a defibrillation coil electrode and a pace/sense electrode(s) are concurrently positioned substantially over the ventricle when implanted are described. The leads include an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance, a first electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment and the second segment of the defibrillation electrode, and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
Description
- This application claims the benefit of U.S. Provisional Application No. 61/984,148, filed on Apr. 25, 2014, the entire content of which is incorporated herein by reference in its entirety.
- The present application relates to electrical stimulation leads and, more particularly, electrical stimulation leads with improved sensing and/or pacing capability for use in extravascular applications.
- Malignant tachyarrhythmia, for example, ventricular fibrillation (VF), is an uncoordinated contraction of the cardiac muscle of the ventricles in the heart, and is the most commonly identified arrhythmia in cardiac arrest patients. If this arrhythmia continues for more than a few seconds, it may result in cardiogenic shock and cessation of effective blood circulation. As a consequence, sudden cardiac death (SCD) may result in a matter of minutes.
- In patients at high risk of ventricular fibrillation, the use of an implantable cardioverter defibrillator (ICD) system has been shown to be beneficial at preventing SCD. An ICD system includes an ICD, which is a battery powered electrical stimulation device, that may include an electrical housing electrode (sometimes referred to as a can electrode), that is coupled to one or more electrical stimulation leads. The electrical stimulation leads may be placed within the heart, within vasculature near the heart (e.g., within the coronary sinus), attached to the outside surface of the heart (e.g., in the pericardium or epicardium), or implanted subcutaneously above the ribcage/sternum. If an arrhythmia is detected, the ICD may generate and deliver a pulse (e.g., cardioversion or defibrillation shock) via the electrical stimulation leads to shock the heart and restore its normal rhythm.
- Subcutaneously implanted electrical stimulation leads or substernally implanted electrical stimulation leads do not intimately contact the heart, but instead reside in a plane of tissue or muscle between the skin and sternum for subcutaneous, or reside in a plane of tissue or muscle between the sternum and the heart for substernal. Due to the distance between the heart and electrodes of the electrical stimulation leads, to achieve improved pacing, sensing, and/or defibrillation, the pace/sense electrodes and the defibrillation coil electrode should be positioned in the plane of tissue such that the electrodes are located directly above or proximate the ventricular surface of the cardiac silhouette. For example, the electrode(s) used to deliver pacing pulses should be positioned in a vector over substantially the center of the chamber to be paced to produce the lowest pacing capture thresholds for pacing. Likewise, the electrode(s) used to sense cardiac electrical activity of the heart should be positioned over substantially the center the chamber to be sensed to obtain the best sensed signal. For shocking purposes, it is preferred to have the defibrillation coil electrode positioned over substantially the center the chamber to be shocked.
- Current medical electrical lead designs used for subcutaneous defibrillation include a single defibrillation coil electrode located between a first pace/sense electrode distal to the defibrillation coil and a second pace/sense electrode proximal to the defibrillation coil. In such a configuration, it is not possible to concurrently position both the defibrillation coil electrode and one of the first and second pace/sense electrode(s) substantially over the center the ventricle. Electrical stimulation leads described herein are designed such that concurrent positioning of the defibrillation electrode and the pace/sense electrode is possible.
- In one example, this disclosure is directed to an implantable medical electrical lead comprising an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance, a first electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment and the second segment of the defibrillation electrode, and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
- In another example, this disclosure is directed to an implantable medical electrical lead comprising an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by approximately 1-3 centimeters (cm), and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
- In a further example, this disclosure is directed to an extravascular implantable cardioverter-defibrillator system comprising an implantable cardioverter-device (ICD) that includes a therapy module configured to generate and deliver electrical stimulation therapy and an implantable medical electrical lead electrically coupled to the therapy module. The lead includes an elongated lead body having a distal portion and a proximal end, a connector at the proximal end of the lead body, a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance, and at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
- This summary is intended to provide an overview of the subject matter described in this disclosure. It is not intended to provide an exclusive or exhaustive explanation of the techniques as described in detail within the accompanying drawings and description below. Further details of one or more examples are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the statements provided below.
-
FIGS. 1A and 1B are conceptual drawings illustrating various views of a patient implanted with an example extravascular implantable cardioverter-defibrillator (ICD) system. -
FIG. 2 is a drawing illustrating a distal portion of an example implantable medical electrical lead. -
FIGS. 3A-3C are conceptual drawings illustrating various views of a patient implanted with an example extravascular ICD system in which a distal portion of the lead is implanted substernally. -
FIG. 4 is a block diagram illustrating components of an example ICD. -
FIGS. 1A and 1B are conceptual diagrams of an extravascular implantable cardioverter-defibrillator (ICD)system 10 subcutaneously implanted within apatient 12.FIG. 1A is a front view ofICD system 10 implanted withinpatient 12.FIG. 1B is a side view ofICD system 10 implanted withinpatient 12.ICD system 10 includes an ICD 14 connected to a medicalelectrical lead 16.FIGS. 1A and 1B are described in the context of an ICD system capable of providing defibrillation and/or cardioversion shocks and, in some instances, pacing pulses. However, the techniques of this disclosure may also be used in the context of other implantable medical devices configured to provide electrical stimulation pulses to stimulate other portions of the body ofpatient 12. - ICD 14 may include a housing that forms a hermetic seal that protects components of ICD 14. The housing of ICD 14 may be formed of a conductive material, such as titanium or titanium alloy, that may function as a housing electrode (sometimes referred to as a can electrode). ICD 14 may also include a connector assembly (also referred to as a connector block or header) that includes electrical feedthroughs through which electrical connections are made between conductors of
lead 16 and electronic components included within the housing ofICD 14. As will be described in further detail herein, housing may house one or more processors, memories, transmitters, receivers, sensors, sensing circuitry, therapy circuitry, power sources and other appropriate components. The housing is configured to be implanted in a patient, such aspatient 12. ICD 14 is implanted subcutaneously on the left side ofpatient 12 above the ribcage. ICD 14 may, in some instances, be implanted between the left posterior axillary line and the left anterior axillary line ofpatient 12. ICD 14 may, however, be implanted at other subcutaneous locations onpatient 12 as described later. -
Lead 16 includes an elongated lead body having a proximal end that includes a connector (not shown) configured to be connected to ICD 14 and a distal portion that includes electrodes 24 (formed byelectrode segments Lead 16 extends subcutaneously above the ribcage fromICD 14 toward a center of the torso ofpatient 12, e.g., towardxiphoid process 20 ofpatient 12. At a location nearxiphoid process 20, lead 16 bends or turns and extends superior subcutaneously above the ribcage and/or sternum, substantially parallel tosternum 22. Although illustrated inFIGS. 1A and 1B as being offset laterally from and extending substantially parallel tosternum 22,lead 16 may be implanted at other locations, such as oversternum 22, offset to the right or left ofsternum 22, angled lateral fromsternum 22 at either the proximal or distal end, or the like. - The elongated lead body of
lead 16 contains a plurality of elongated electrical conductors (not illustrated) that extend within the lead body from the connector at the proximal lead end toelectrodes lead 16. The elongated lead body may have a generally uniform shape along the length of the lead body. In one example, the elongated lead body may have a generally tubular or cylindrical shape along the length of the lead body. The elongated lead body may have a diameter of between 3 and 9 French (Fr) in some instances. However, lead bodies of less than 3 Fr and more than 9 Fr may also be utilized. In another example, the distal portion (or all of) the elongated lead body may have a flat, ribbon or paddle shape. In this instance, the width across the flat portion of the flat, ribbon or paddle shape may be between 1 and 3.5 mm. Other lead body designs may be used without departing from the scope of this disclosure. The lead body oflead 16 may be formed from a non-conductive material, including silicone, polyurethane, fluoropolymers, mixtures thereof, and other appropriate materials, and shaped to form one or more lumens within which the one or more conductors extend. However, the techniques are not limited to such constructions. - The one or more elongated electrical conductors contained within the lead body of
lead 16 may engage withrespective electrodes electrodes Electrode segments segments electrode segments ICD 14 via connections in the connector assembly, including associated feedthroughs. The electrical conductors transmit therapy from a therapy module withinICD 14 to one or more of electrodes 24 (or one ofsegments segments ICD 14. - Defibrillation electrode 24 is located toward the distal portion of
defibrillation lead 16, e.g., toward the portion ofdefibrillation lead 16 extending superior nearsternum 22. As indicated above, defibrillation electrode 24 is formed of afirst electrode segment 24A and asecond electrode segment 24B separated by a distance. In one example,first segment 24A andsecond segment 24B are each approximately 2-5 cm in length and the proximal end ofsegment 24A is separated by approximately 1-3 cm from the distal end ofsegment 24B. Thefirst electrode segment 24A and thesecond electrode segment 24B of defibrillation electrode 24 may in one example be coil electrode segments. In other embodiments, however, defibrillation electrode 24 may be a flat ribbon electrode, paddle electrode, braided or woven electrode, mesh electrode, directional electrode, patch electrode or other type of electrode that is segmented in the manner described herein. Moreover, in other examples, defibrillation electrode 24 may be constructed of more than two segments. - A total length of defibrillation electrode 24 may vary depending on a number of variables. Defibrillation electrode 24 may, in one example, have a total length (e.g., length of the two segments combined) of between approximately 5-10 centimeters (cm). However, defibrillation electrode 24 may have a total length less than 5 cm and greater than 10 cm in other embodiments. In another example, defibrillation electrode 24 may have a total length of approximately 2-16 cm. In some instances,
defibrillation segments defibrillation segments defibrillation segments -
Defibrillation lead 16 also includeselectrodes defibrillation lead 16. In the example illustrated inFIGS. 1A and 1B ,electrodes defibrillation electrode segments electrode 30 is located distal ofdefibrillation electrode segment 24A.Electrodes electrode 30 is illustrated as a hemispherical tip electrode. However,electrodes electrodes electrodes electrode 30 may be formed into a partial-hemispherical electrode in a similar manner as described above with respect to ringelectrodes electrodes -
Electrodes lead 16 may have substantially the same outer diameter as the lead body. In one example,electrodes Electrodes -
Electrodes electrodes lead 16. In one example,electrodes electrodes electrodes Electrode 30 is spaced apart from the distal end ofdefibrillation electrode segment 24A by a distance, which may again be less than 2 cm. However,electrode 30 may be spaced apart from the distal end ofdefibrillation electrode segment 24A by more than 2 cm. - The example dimensions provided above are exemplary in nature and should not be considered limiting of the embodiments described herein. In other embodiments, lead 16 may include less than three pace/sense electrodes or more than three pace/sense electrodes. In further instances, the pace/sense electrodes may be located elsewhere along the length of
lead 16, e.g., distal todefibrillation electrode segment 24A or proximal todefibrillation electrode segment 24B, with one or more of the sense/pace electrodes being located betweendefibrillation electrode segments electrode 28 located between the proximal segment and middle segment andelectrode 29 located between the middle segment and the distal segment. - To achieve improved sensing and/or pacing, it is desirable to have the pace/sense electrodes located substantially over the chamber of
heart 26 that is being paced and/or sensed. For example, it is desirable to locate the pace/sense electrodes over a cardiac silhouette of the ventricle as observed via an anterior-posterior (AP) fluoroscopic view ofheart 26 for sensing or pacing the ventricle. Likewise, to achieve improved defibrillation therapy, it is desirable to have the defibrillation electrode located substantially over the chamber ofheart 26 to which the defibrillation or cardioversion shock is being applied, e.g., over a cardiac silhouette of the ventricle as observed via an AP fluoroscopic view ofheart 26. In conventional subcutaneous lead designs, it is only possible to position either the defibrillation electrode or the sense electrode over the relevant chamber, but not both. - Leads designed in accordance with any of the techniques described herein can be implanted to achieve desirable electrode positioning for both defibrillation and pacing/sensing. In particular, lead 16 may be implanted such that
electrodes heart 26. In other words, lead 16 may be implanted such that one or both of a unipolar pacing/sensing vector fromelectrode ICD 14 are substantially across the ventricles ofheart 26. The therapy vector may be viewed as a line that extends from a point onelectrode electrode ICD 14, e.g., center of the housing electrode. In another example, the spacing betweenelectrodes lead 16 may be such that a bipolar pacing vector betweenelectrode 28 andelectrode 29 is centered or otherwise located substantially over the ventricle. -
Electrode 30 may be located over the cardiac silhouette of the atrium or near the top of the cardiac silhouette of the atrium as observed via an AP fluoroscopic view. As such,electrode 30 may offer an alternate sensing vector and/or provide atrial pacing if needed or desired. - Not only are
electrodes defibrillation electrode segments heart 26. As such, the therapy vector fromdefibrillation electrode segments ICD 14 is substantially across the ventricles ofheart 26. - In some instances,
electrodes lead 16 may be shaped, oriented, designed or otherwise configured to reduce extra-cardiac stimulation. For example,electrodes lead 16 may be shaped, oriented, designed, partially insulated or otherwise configured to focus, direct orpoint electrodes heart 26. In this manner, pacing pulses delivered vialead 16 are directed towardheart 26 and not outward toward skeletal muscle. For example,electrodes lead 16 may be partially coated or masked with a polymer (e.g., polyurethane) or another coating material (e.g., tantalum pentoxide) on one side or in different regions so as to direct the pacing signal towardheart 26 and not outward toward skeletal muscle. In the case of a ring electrode, for example, the ring electrode may be partially coated with the polymer or other material to form a half-ring electrode, quarter-ring electrode, or other partial-ring electrode. -
ICD 14 may obtain sensed electrical signals corresponding with electrical activity ofheart 26 via a combination of sensing vectors that include combinations ofelectrodes ICD 14. For example,ICD 14 may obtain electrical signals sensed using a sensing vector between any two ofelectrodes electrodes ICD 14. In some instances,ICD 14 may even obtain sensed electrical signals using a sensing vector that includes one or bothsegments electrodes ICD 14. -
ICD 14 analyzes the sensed electrical signals obtained from one or more of the sensing vectors oflead 16 to monitor for tachyarrhythmia, such as ventricular tachycardia (VT) or ventricular fibrillation (VF).ICD 14 may analyze the heart rate and/or morphology of the sensed electrical signals to monitor for tachyarrhythmia in accordance with any of a number of techniques known in the art. One example technique for detecting tachyarrhythmia is described in U.S. Pat. No. 7,761,150 to Ghanem et al., entitled “METHOD AND APPARATUS FOR DETECTING ARRHYTHMIAS IN A MEDICAL DEVICE.” The entire content of the tachyarrhythmia detection algorithm described in Ghanem et al. are incorporated by reference herein in their entirety. -
ICD 14 generates and delivers electrical stimulation therapy in response to detecting tachycardia (e.g., VT or VF). In response to detecting the tachycardia,ICD 14 may deliver one or more cardioversion or defibrillation shocks via defibrillation electrode 24 oflead 16.ICD 14 may deliver the cardioversion or defibrillation shocks using either of theelectrode segments ICD 14 may generate and deliver electrical stimulation therapy other than cardioversion or defibrillation shocks, including post-shock pacing using a therapy vector formed from one or more ofelectrodes - The examples illustrated in
FIGS. 1A and 1B are exemplary in nature and should not be considered limiting of the techniques described in this disclosure. In other examples,ICD 14 and lead 16 may be implanted at other locations. For example,ICD 14 may be implanted in a subcutaneous pocket in the right pectoral region. In this example,defibrillation lead 16 may extend subcutaneously from the device toward the manubrium ofsternum 22 and bend or turn and extend inferior from the manubrium to the desired location. In yet another example,ICD 14 may be placed abdominally or intrathoracically.Lead 16 may be implanted in other extravascular locations as well. For instance, as described with respect toFIGS. 3A-3C , lead 16 may be implanted underneath the sternum/ribcage. - In the example illustrated in
FIG. 1 ,system 10 is an ICD system that provides cardioversion/defibrillation and, in some instances, pacing therapy. However, these techniques may be applicable to other cardiac systems, including cardiac resynchronization therapy defibrillator (CRT-D) systems or other cardiac stimulation therapies, or combinations thereof. For example,ICD 14 may be configured to provide electrical stimulation pulses to stimulate nerves, skeletal muscles, diaphragmatic muscles, e.g., for various neuro-cardiac applications and/or for sleep apnea or respiration therapy. As another example, lead 16 may be placed further superior such that the defibrillation electrode 24 is placed substantially over the atrium ofheart 26 to provide a shock or pulse to the atrium to terminate atrial fibrillation (AF). In still other examples,defibrillation lead 16 may include a second defibrillation electrode (e.g., second elongated coil electrode) near a proximal end oflead 16 or near a middle portion oflead 16. -
FIG. 2 is a conceptual diagram illustrating a distal portion of another example implantableelectrical lead 40 with improved pacing and/or sensing capability for use in non-vascular, extra-pericardial applications.Lead 40 can include one or more of the structure and/or functionality oflead 16 ofFIGS. 1A and 1B (and vice versa). Repetitive description of like numbered elements described in other embodiments is omitted for sake of brevity.Lead 40 may be used in place oflead 16 inICD system 10 ofFIGS. 1A and 1B . -
Lead 40 conforms substantially withlead 16 ofFIGS. 1A and 1B , but instead of havingring electrodes defibrillation segments sense coil electrode 42 betweendefibrillation segments sense ring electrode 44 proximal todefibrillation electrode segment 24B. Such a configuration may increase the surface area located over the ventricles. - The length of pace/
sense coil electrode 42 may be dependent upon the spacing betweendefibrillation segments defibrillation segments sense coil electrode 42 may have a length of approximately 1 cm. However, other spacings and lengths greater than or less than 1 cm may be used, including the ranges provided above with respect toFIGS. 1A and 1B .ICD 14 may be configured to sense and deliver pacing and/or cardioversion/defibrillation using any combination ofelectrodes Lead 40 may be implanted such thatelectrode 42 and defibrillation electrode 24 is subtantially over the ventricular surface of the cardiac silhouette in the same manner as described above with respsect toFIGS. 1A and 1B . -
FIGS. 3A-3C are conceptual diagrams ofpatient 12 implanted with anotherexample ICD system 110.FIG. 3A is a front view ofpatient 12 implanted withICD system 110.FIG. 3B is a side view ofpatient 12 implanted withICD system 110.FIG. 3C is a transverse view ofpatient 12 withICD system 110.ICD system 110 can include one or more of the structure and/or functionality ofsystem 10 ofFIGS. 1A-1B (and vice versa).ICD system 110 ofFIGS. 3A-3C is illustrated withlead 16 for purposes of illustration, but may be utilized with any ofleads -
ICD system 110 conforms substantially toICD system 10 ofFIGS. 1A-1B , exceptdefibrillation lead 16 ofsystem 110 is implanted at least partially underneathsternum 22 ofpatient 12.Lead 16 extends subcutaneously fromICD 14 towardxiphoid process 20, and at a location nearxiphoid process 20 bends or turns and extends superior underneath/belowsternum 22 withinanterior mediastinum 36.Anterior mediastinum 36 may be viewed as being bounded laterally bypleurae 39, posteriorly bypericardium 38, and anteriorly bysternum 22. In some instances, the anterior wall ofanterior mediastinum 36 may also be formed by the transversus thoracis and one or more costal cartilages.Anterior mediastinum 36 includes a quantity of loose connective tissue (such as areolar tissue), some lymph vessels, lymph glands, substernal musculature (e.g., transverse thoracic muscle), branches of the internal thoracic artery, and the internal thoracic vein. In one example, the distal portion oflead 16 extends along the posterior side ofsternum 22 substantially within the loose connective tissue and/or substernal musculature ofanterior mediastinum 36. A lead implanted such that the distal portion is substantially withinanterior mediastinum 36 will be referred to herein as a substernal lead. Also, electrical stimulation, such as pacing, cardioversion or defibrillation, provided bylead 16 implanted substantially withinanterior mediastinum 36 will be referred to herein as substernal electrical stimulation, substernal pacing, substernal cardioversion, or substernal defibrillation. - The distal portion of
lead 16 is described herein as being implanted substantially withinanterior mediastinum 36. Thus, points along the distal portion oflead 16 may extend out ofanterior mediastinum 36, but the majority of the distal portion is withinanterior mediastinum 36. In other embodiments, the distal portion oflead 16 may be implanted in other non-vascular, extra-pericardial locations, including the gap, tissue, or other anatomical features around the perimeter of and adjacent to, but not attached to, the pericardium or other portion ofheart 26 and not abovesternum 22 or ribcage. As such, lead 16 may be implanted anywhere within the “substernal space” defined by the undersurface between the sternum and/or ribcage and the body cavity but not including the pericardium or other portion ofheart 26. The substernal space may alternatively be referred to by the terms “retrosternal space” or “mediastinum” or “infrasternal” as is known to those skilled in the art and includes theanterior mediastinum 36. The substernal space may also include the anatomical region described in Baudoin, Y. P., et al., entitled “The superior epigastric artery does not pass through Larrey's space (trigonum sternocostale).” Surg. Radiol. Anat. 25.3-4 (2003): 259-62 as Larrey's space. In other words, the distal portion oflead 16 may be implanted in the region around the outer surface ofheart 26, but not attached toheart 26. - The distal portion of
lead 16 may be implanted substantially withinanterior mediastinum 36 such thatelectrodes heart 26. To achieve improved sensing and/or pacing, it is desirable to have the pace/sense electrodes located substantially over the chamber ofheart 26 that is being paced and/or sensed. For instance, lead 16 may be implanted withinanterior mediastinum 36 such that 28 and 29 are located over a cardiac silhouette of one or both ventricles as observed via an AP fluoroscopic view ofheart 26. In other words, lead 16 may be implanted such that one or both of a unipolar pacing/sensing vector fromelectrode ICD 14 are substantially across the ventricles ofheart 26. In another example, the spacing betweenelectrodes lead 16 may be such that a bipolar pacing vector betweenelectrode 28 andelectrode 29 is centered or otherwise located over the ventricle. - Likewise, to achieve improved defibrillation therapy, it is desirable to have the defibrillation electrode located substantially over the chamber of
heart 26 to which the defibrillation or cardioversion shock is being applied, e.g., over a cardiac silhouette of the ventricle as observed via an AP fluoroscopic view ofheart 26. In conventional subcutaneous lead designs, it is only possible to position either the defibrillation electrode or the sense electrode over the relevant chamber, but not both. Thus, not only areelectrodes lead 16,defibrillation electrode segments heart 26. In this manner, lead 16 is designed to provide desirable electrode positioning for both defibrillation and pacing/sensing concurrently. - In the example illustrated in
FIGS. 3A-3C , lead 16 is located substantially centered understernum 22. In other instances, however, lead 16 may be implanted such that it is offset laterally from the center ofsternum 22. In some instances, lead 16 may extend laterally enough such that all or a portion oflead 16 is underneath/below the ribcage in addition to or instead ofsternum 22. - Placing
lead 16 in the substernal space may provide a number of advantages. For example, placinglead 16 in the substernal space may significantly reduce the amount of energy that needs to be delivered to defibrillateheart 26. In some instances,ICD 14 may generate and deliver cardioversion or defibrillation shocks having energies of less than 65 Joules (J), less than 60 J, between 35-60 J, and in some cases possibly less than 35 J. As such, placingdefibrillation lead 16 within the substernal space, e.g., with the distal portion substantially withinanterior mediastinum 36, may result in reduced energy consumption and, in turn, smaller devices and/or devices having increased longevity. - Another advantage of placing
lead 16 in the substernal space is that pacing, such as anti-tachycadia pacing (ATP), post-shock pacing and, in some cases, bradycardia pacing, may be provided bysystem 110. For example,ICD 14 may deliver one or more sequences of ATP in an attempt to terminate a detected VT without delivering a defibrillation shock. The ATP may be delivered via one or more therapy vectors oflead 16, e.g., unipolar therapy vector, bipolar pacing vector or multipolar pacing vector, formed usingelectrodes ICD 14, and/or defibrillation electrode 24 or individualdefibrillation electrode segments ICD 14 is not configured to deliver ATP,ICD 14 may deliver one or more cardioversion or defibrillation shocks via defibrillation electrode 24 oflead 16.ICD 14 may deliver the cardioversion or defibrillation shocks using either of theelectrode segments ICD 14 may generate and deliver electrical stimulation therapy other than ATP, cardioversion or defibrillation shocks, including post-shock pacing, bradycardia pacing, or other electrical stimulation therapy using a therapy vector formed from one or more ofelectrodes -
FIG. 4 is a functional block diagram of an example configuration of electronic components of anexample ICD 14.ICD 14 includes acontrol module 60,sensing module 62,therapy module 64,communication module 68, andmemory 70. The electronic components may receive power from apower source 66, which may be a rechargeable or non-rechargeable battery. In other embodiments,ICD 14 may include more or fewer electronic components. The described modules may be implemented together on a common hardware component or separately as discrete but interoperable hardware or software components. Depiction of different features as modules is intended to highlight different functional aspects and does not necessarily imply that such modules must be realized by separate hardware or software components. Rather, functionality associated with one or more modules may be performed by separate hardware or software components, or integrated within common or separate hardware or software components.FIG. 4 will be described in the context of ICD being coupled to lead 16 for exemplary purposes only. However,ICD 14 may be coupled to other leads, such aslead 40 described herein, and thus other electrodes, such aselectrodes -
Sensing module 62 is electrically coupled to some or all of electrodes 24 (or separately tosegments 24A and/or 24B), 28, 29, and 30 via the conductors oflead 16 and one or more electrical feedthroughs, or to the housing electrode via conductors internal to the housing ofICD 14.Sensing module 62 is configured to obtain signals sensed via one or more combinations of electrodes 24 (orsegments 24A and/or 24B), 28, 29, and 30 and the housing electrode ofICD 14 and process the obtained signals. - The components of
sensing module 62 may be analog components, digital components or a combination thereof.Sensing module 62 may, for example, include one or more sense amplifiers, filters, rectifiers, threshold detectors, analog-to-digital converters (ADCs) or the like.Sensing module 62 may convert the sensed signals to digital form and provide the digital signals to controlmodule 60 for processing or analysis. For example,sensing module 62 may amplify signals from the sensing electrodes and convert the amplified signals to multi-bit digital signals by an ADC.Sensing module 62 may also compare processed signals to a threshold to detect the existence of atrial or ventricular depolarizations (e.g., P- or R-waves) and indicate the existence of the atrial depolarization (e.g., P-waves) or ventricular depolarizations (e.g., R-waves) to controlmodule 60. -
Control module 60 may process the signals from sensingmodule 62 to monitor electrical activity ofheart 26 ofpatient 12.Control module 60 may store signals obtained by sensingmodule 62 as well as any generated EGM waveforms, marker channel data or other data derived based on the sensed signals inmemory 70.Control module 60 may analyze the EGM waveforms and/or marker channel data to detect cardiac events (e.g., tachycardia). In response to detecting the cardiac event,control module 60 may controltherapy module 64 to deliver the desired therapy to treat the cardiac event, e.g., defibrillation shock, cardioversion shock, ATP, post-shock pacing, or bradycardia pacing. -
Therapy module 64 is configured to generate and deliver electrical stimulation therapy toheart 26.Therapy module 64 may include one or more pulse generators, capacitors, and/or other components capable of generating and/or storing energy to deliver as pacing therapy, defibrillation therapy, cardioversion therapy, cardiac resynchronization therapy, other therapy or a combination of therapies. In some instances,therapy module 64 may include a first set of components configured to provide pacing therapy and a second set of components configured to provide defibrillation therapy. In other instances,therapy module 64 may utilize the same set of components to provide both pacing and defibrillation therapy. In still other instances,therapy module 64 may share some of the defibrillation and pacing therapy components while using other components solely for defibrillation or pacing. -
Control module 60 may controltherapy module 64 to deliver the generated therapy toheart 26 via one or more combinations of electrodes 24 (or separately tosegments 24A and/or 24B), 28, 29, and 30 oflead 16 and the housing electrode ofICD 14 according to one or more therapy programs, which may be stored inmemory 70. In instances in which controlmodule 60 is coupled to a different lead, e.g., lead 40, other electrodes may be utilized, such aselectrodes Control module 60controls therapy module 64 to generate electrical stimulation therapy with the amplitudes, pulse widths, timing, frequencies, electrode combinations or electrode configurations specified by a selected therapy program. -
Therapy module 64 may include a switch module to select which of the available electrodes are used to deliver the therapy. The switch module may include a switch array, switch matrix, multiplexer, or any other type of switching device suitable to selectively couple electrodes totherapy module 64.Control module 60 may select the electrodes to function as therapy electrodes, or the therapy vector, via the switch module withintherapy module 64. In instances in whichdefibrillation segments control module 60 may be configured to selectively coupletherapy module 64 to either one ofsegments segments therapy module 64 andsensing module 62. In other instances, each ofsensing module 62 andtherapy module 64 may have separate switch modules. - In the case of pacing therapy being provided from the substernal space, e.g., ATP, post-shock pacing, and/or bradycardia pacing provided via
electrodes segments lead 16,control module 60controls therapy module 64 to generate and deliver pacing pulses with any of a number of shapes, amplitudes, pulse widths, or other characteristic to captureheart 26. For example, the pacing pulses may be monophasic, biphasic, or multi-phasic (e.g., more than two phases). The pacing thresholds ofheart 26 when delivering pacing pulses from the substernal space, e.g., fromelectrodes anterior mediastinum 36, may depend upon a number of factors, including location, type, size, orientation, and/or spacing ofelectrodes ICD 14 relative toelectrodes - The increased distance from
electrodes lead 16 to the heart tissue may result inheart 26 having increased pacing thresholds compared to transvenous pacing thresholds. To this end,therapy module 64 may be configured to generate and deliver pacing pulses having larger amplitudes and/or pulse widths than conventionally required to obtain capture via leads implanted within the heart (e.g., transvenous leads) or leads attached directly toheart 26. In one example,therapy module 64 may generate and deliver pacing pulses having amplitudes of less than or equal to 8 volts and pulse widths between 0.5-3.0 milliseconds. In another example,therapy module 64 may generate and deliver pacing pulses having amplitudes of between 5 and 10 volts and pulse widths between approximately 3.0 milliseconds and 10.0 milliseconds. In another example,therapy module 64 may generate and deliver pacing pulses having pulse widths between approximately 2.0 milliseconds and 8.0 milliseconds. In a further example,therapy module 64 may generate and deliver pacing pulses having pulse widths between approximately 0.5 milliseconds and 20.0 milliseconds. In another example,therapy module 64 may generate and deliver pacing pulses having pulse widths between approximately 1.5 milliseconds and 20.0 milliseconds. - Pacing pulses having longer pulse durations than conventional transvenous pacing pulses may result in lower energy consumption. As such,
therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than two (2) milliseconds. In another example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of between greater than two (2) milliseconds and less than or equal to three (3) milliseconds. In another example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to three (3) milliseconds. In another example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to five (5) milliseconds. In another example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to ten (10) milliseconds. In a further example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths between approximately 3-10 milliseconds. In a further example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to fifteen (15) milliseconds. In yet another example,therapy module 64 may be configured to generate and deliver pacing pulses having pulse widths or durations of greater than or equal to twenty (20) milliseconds. - Depending on the pulse widths,
ICD 14 may be configured to deliver pacing pulses having pulse amplitudes less than or equal to twenty (20) volts, deliver pacing pulses having pulse amplitudes less than or equal to ten (10) volts, deliver pacing pulses having pulse amplitudes less than or equal to five (5) volts, deliver pacing pulses having pulse amplitudes less than or equal to two and one-half (2.5) volts, deliver pacing pulses having pulse amplitudes less than or equal to one (1) volt. In other examples, the pacing pulse amplitudes may be greater than 20 volts. Typically the lower amplitudes require longer pacing widths as illustrated in the experimental results. Reducing the amplitude of pacing pulses delivered byICD 14 reduces the likelihood of extra-cardiac stimulation and lower consumed energy ofpower source 66. Some experimental results are provided later illustrating some example combinations of pacing amplitudes and widths. - For pacing therapy provided from the subcutaneous placement of
lead 16 above the sternum and/or ribcage, pacing amplitudes and pulse widths may vary. - In the case of cardioversion or defibrillation therapy, e.g., cardioversion or defibrillation shocks provided by
defibrillation electrode segments 24A and/or 24B (individually or together),control module 60controls therapy module 64 to generate cardioversion or defibrillation shocks having any of a number of waveform properties, including leading-edge voltage, tilt, delivered energy, pulse phases, and the like.Therapy module 64 may, for instance, generate monophasic, biphasic or multiphasic waveforms. Additionally,therapy module 64 may generate cardioversion or defibrillation waveforms having different amounts of energy. As with pacing, delivering cardioversion or defibrillation shocks from the substernal space, e.g., from electrode 24 substantially withinanterior mediastinum 36, may reduce the amount of energy that needs to be delivered to defibrillateheart 26. Whenlead 16 is implanted in the substernal space,therapy module 64 may generate and deliver cardioversion or defibrillation shocks having energies of less than 65 J, less than 60 J, between 40-50 J, between 35-60 J, and in some instances less than 35 J. Whenlead 16 is implanted subcutaneously,ICD 14 may generate and deliver cardioversion or defibrillation shocks having energies around 65-80 J. -
Therapy module 64 may also generate defibrillation waveforms having different tilts. In the case of a biphasic defibrillation waveform,therapy module 64 may use a 65/65 tilt, a 50/50 tilt, or other combinations of tilt. The tilts on each phase of the biphasic or multiphasic waveforms may be the same in some instances, e.g., 65/65 tilt. However, in other instances, the tilts on each phase of the biphasic or multiphasic waveforms may be different, e.g., 65 tilt on the first phase and 55 tilt on the second phase. The example delivered energies, leading-edge voltages, phases, tilts, and the like are provided for example purposes only and should not be considered as limiting of the types of waveform properties that may be utilized to provide substernal defibrillation via defibrillation electrode 24. -
Communication module 68 includes any suitable hardware, firmware, software or any combination thereof for communicating with another device, such as a clinician programmer, a patient monitoring device, or the like. For example,communication module 68 may include appropriate modulation, demodulation, frequency conversion, filtering, and amplifier components for transmission and reception of data with the aid ofantenna 72.Antenna 72 may be located within connector block ofICD 14 or withinhousing ICD 14. - The various modules of
ICD 14 may include any one or more processors, controllers, digital signal processors (DSPs), application specific integrated circuits (ASICs), field-programmable gate arrays (FPGAs), or equivalent discrete or integrated circuitry, including analog circuitry, digital circuitry, or logic circuitry.Memory 70 may include computer-readable instructions that, when executed bycontrol module 60 or other component ofICD 14, cause one or more components ofICD 14 to perform various functions attributed to those components in this disclosure.Memory 70 may include any volatile, non-volatile, magnetic, optical, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), static non-volatile RAM (SRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other non-transitory computer-readable storage media. - Various examples have been described. These and other examples are within the scope of the following claims.
Claims (20)
1. An implantable medical electrical lead comprising:
an elongated lead body having a distal portion and a proximal end;
a connector at the proximal end of the lead body;
a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance;
a first electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment and the second segment of the defibrillation electrode; and
at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
2. The lead of claim 1 , wherein the at least one pace/sense electrode comprises a first pace/sense electrode and a second pace/sense electrode located between the first segment and the second segment, the implantable medical electrical lead further comprising:
a second electrical conductor extending from the connector at the proximal end of the lead body and electrically coupling to the first pace/sense electrode; and
a third electrical conductor extending from the connector at the proximal end of the lead body and electrically coupling to the second pace/sense electrode.
3. The lead of claim 2 , wherein the first and second pace/sense electrodes located between the first segment and the second segment comprise one of or a combination of ring electrodes, hemispherical electrodes, coil electrodes, partial-ring electrodes, partial-hemispherical electrodes, partial-coil electrodes.
4. The lead of claim 1 , further comprising at least one pace/sense electrode located distal to the first segment of the defibrillation electrode.
5. The lead of claim 1 , further comprising at least one pace/sense electrode located proximal to the second segment of the defibrillation electrode.
6. The lead of claim 1 , wherein the at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode comprises a coil electrode or partial-coil electrode.
7. The lead of claim 1 , wherein the distance between the first segment and the second segment is between approximately 1-3 centimeters (cm).
8. The lead of claim 1 , wherein the distal portion of the lead is arranged such that when the lead is implanted the at least one pace/sense electrode and the defibrillation electrode are both substantially centered over a ventricle of a heart of the patient.
9. An implantable medical electrical lead comprising:
an elongated lead body having a distal portion and a proximal end;
a connector at the proximal end of the lead body;
a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by approximately 1-3 centimeters (cm); and
at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
10. The lead of claim 9 , further comprising an electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment and the second segment of the defibrillation electrode.
11. The lead of claim 9 , further comprising:
a first electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment of the defibrillation electrode; and
a second electrical conductor extending from the proximal end of the lead body and electrically coupling to the second segment of the defibrillation electrode.
12. The lead of claim 9 , wherein the at least one pace/sense electrode comprises at least two pace/sense electrodes located between the first segment and the second segment.
13. The lead of claim 9 , wherein the at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode comprises a coil electrode.
14. The lead of claim 9 , further comprising at least one of a pace/sense electrode located distal to the first segment of the defibrillation electrode and a pace/sense electrode located proximal to the second segment of the defibrillation electrode.
15. The lead of claim 9 , wherein the distal portion of the lead is configured such that when the lead is implanted the at least one pace/sense electrode and the defibrillation electrode are both substantially centered over a ventricle of a heart of the patient.
16. An implantable cardioverter-defibrillator system comprising:
an implantable cardioverter-device (ICD) that includes a therapy module configured to generate and deliver electrical stimulation therapy; and
an implantable medical electrical lead electrically coupled to the therapy module, wherein the lead comprises:
an elongated lead body having a distal portion and a proximal end;
a connector at the proximal end of the lead body;
a defibrillation electrode located along the distal portion of the lead body, wherein the defibrillation electrode includes a first segment and a second segment proximal to the first segment by a distance; and
at least one pace/sense electrode located between the first segment and the second segment of the defibrillation electrode.
17. The system of claim 16 , wherein the lead further comprises an electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment and the second segment of the defibrillation electrode.
18. The system of claim 16 , wherein
the lead further comprises:
a first electrical conductor extending from the proximal end of the lead body and electrically coupling to the first segment of the defibrillation electrode; and
a second electrical conductor extending from the proximal end of the lead body and electrically coupling to the second segment of the defibrillation electrode, and
the ICD further comprises a switching array configured to selectively couple the therapy module to any one of just the first segment of the defibrillation electrode, just the second segment of the defibrillation electrode, and both the first and second segments of the defibrillation electrode simultaneously.
19. The system of claim 16 , wherein the distance between the first segment and the second segment is between approximately 1-3 centimeters (cm).
20. The system of claim 16 , wherein the distal portion of the lead is arranged such that when the lead is implanted the at least one pace/sense electrode and the defibrillation electrode are both substantially centered over a ventricle of a heart of the patient.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/519,436 US20150306375A1 (en) | 2014-04-25 | 2014-10-21 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
EP23164085.5A EP4223357B1 (en) | 2014-04-25 | 2015-04-24 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
CN201580032591.3A CN106413809B (en) | 2014-04-25 | 2015-04-24 | Electro photoluminescence lead outside implantable vessel with improved sensing and pace-making ability |
EP15721469.3A EP3134169B1 (en) | 2014-04-25 | 2015-04-24 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
PCT/US2015/027478 WO2015164715A1 (en) | 2014-04-25 | 2015-04-24 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984148P | 2014-04-25 | 2014-04-25 | |
US14/519,436 US20150306375A1 (en) | 2014-04-25 | 2014-10-21 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150306375A1 true US20150306375A1 (en) | 2015-10-29 |
Family
ID=54333834
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/519,436 Abandoned US20150306375A1 (en) | 2014-04-25 | 2014-10-21 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US14/695,255 Active US9855414B2 (en) | 2014-04-25 | 2015-04-24 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US15/860,310 Active US10137295B2 (en) | 2014-04-25 | 2018-01-02 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US16/200,846 Active US10661073B2 (en) | 2014-04-25 | 2018-11-27 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US16/879,281 Active 2035-12-10 US11534603B2 (en) | 2014-04-25 | 2020-05-20 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US18/062,714 Pending US20230109342A1 (en) | 2014-04-25 | 2022-12-07 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US18/331,793 Active US12083333B2 (en) | 2014-04-25 | 2023-06-08 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/695,255 Active US9855414B2 (en) | 2014-04-25 | 2015-04-24 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US15/860,310 Active US10137295B2 (en) | 2014-04-25 | 2018-01-02 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US16/200,846 Active US10661073B2 (en) | 2014-04-25 | 2018-11-27 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US16/879,281 Active 2035-12-10 US11534603B2 (en) | 2014-04-25 | 2020-05-20 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US18/062,714 Pending US20230109342A1 (en) | 2014-04-25 | 2022-12-07 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US18/331,793 Active US12083333B2 (en) | 2014-04-25 | 2023-06-08 | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
Country Status (4)
Country | Link |
---|---|
US (7) | US20150306375A1 (en) |
EP (2) | EP4223357B1 (en) |
CN (1) | CN106413809B (en) |
WO (1) | WO2015164715A1 (en) |
Cited By (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9486155B2 (en) | 2015-02-18 | 2016-11-08 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US9526522B2 (en) | 2013-09-27 | 2016-12-27 | Medtronic, Inc. | Interventional medical systems, tools, and assemblies |
US9526909B2 (en) | 2014-08-28 | 2016-12-27 | Cardiac Pacemakers, Inc. | Medical device with triggered blanking period |
WO2017011280A1 (en) | 2015-07-10 | 2017-01-19 | Medtronic, Inc. | Medical tools for gaining access to extravascular spaces |
US9592391B2 (en) | 2014-01-10 | 2017-03-14 | Cardiac Pacemakers, Inc. | Systems and methods for detecting cardiac arrhythmias |
US9669230B2 (en) | 2015-02-06 | 2017-06-06 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
WO2017096257A1 (en) | 2015-12-03 | 2017-06-08 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system for delivering composite pacing pulses |
WO2017096181A1 (en) | 2015-12-03 | 2017-06-08 | Medtronic, Inc. | Extra-cardiovascular pacing using high-voltage therapy circuitry of an implantable cardioverter defibrillator |
US9675261B2 (en) | 2015-01-23 | 2017-06-13 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
WO2017160507A1 (en) | 2016-03-16 | 2017-09-21 | Medtronic, Inc. | Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system |
WO2017172272A1 (en) | 2016-03-30 | 2017-10-05 | Medtronic, Inc. | Medical system for detecting an atrial tachyarrhythmia through classification based on heart rate variability |
WO2017189144A1 (en) | 2016-04-27 | 2017-11-02 | Medtronic, Inc. | System and method for sensing and detection in an extra-cardiovascular implantable cardioverter defibrillator |
WO2017189558A1 (en) | 2016-04-28 | 2017-11-02 | Medtronic, Inc. | Implantable cardioverter defibrillator with asystole detection and pacing response |
WO2017189802A1 (en) | 2016-04-29 | 2017-11-02 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an extracardiovascular implantable cardioverter defibrillator |
WO2017213952A1 (en) | 2016-06-08 | 2017-12-14 | Medtronic, Inc. | System and method for identifying and responding to p-wave oversensing in a cardiac system |
US9853743B2 (en) | 2015-08-20 | 2017-12-26 | Cardiac Pacemakers, Inc. | Systems and methods for communication between medical devices |
US9855414B2 (en) | 2014-04-25 | 2018-01-02 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
WO2018022422A1 (en) | 2016-07-27 | 2018-02-01 | Medtronic, Inc. | Cardiac electrical signal noise detection for tachyarrhythmia episode rejection |
WO2018022676A1 (en) | 2016-07-27 | 2018-02-01 | Medtronic, Inc. | Cardiac electrical signal morphology and pattern-based t-wave oversensing rejection |
WO2018022681A1 (en) | 2016-07-27 | 2018-02-01 | Medtronic, Inc. | Cardiac electrical signal gross morphology-based noise detection for rejection of ventricular tachyarrhythmia detection |
WO2018022861A1 (en) | 2016-07-29 | 2018-02-01 | Medtronic, Inc. | System and method for controlling cardiac pacing mode switching |
US9901276B2 (en) | 2015-02-18 | 2018-02-27 | Medtronic, Inc. | Method and apparatus for identifying sick sinus syndrome in an implantable cardiac monitoring device |
US9956414B2 (en) | 2015-08-27 | 2018-05-01 | Cardiac Pacemakers, Inc. | Temporal configuration of a motion sensor in an implantable medical device |
US9968787B2 (en) | 2015-08-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Spatial configuration of a motion sensor in an implantable medical device |
US10004418B2 (en) | 2015-01-23 | 2018-06-26 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10029107B1 (en) | 2017-01-26 | 2018-07-24 | Cardiac Pacemakers, Inc. | Leadless device with overmolded components |
WO2018140336A1 (en) | 2017-01-26 | 2018-08-02 | Medtronic, Inc. | Noise detection and frequency determination in an extra-cardiovascular implantable cardioverter defibrillator system |
WO2018140343A1 (en) | 2017-01-26 | 2018-08-02 | Medtronic, Inc. | Detection of electromagnetic interference in a cardiac electrical signal by an implantable medical device |
WO2018144665A1 (en) | 2017-02-06 | 2018-08-09 | Medtronic, Inc. | Charge balanced cardiac pacing from high voltage circuitry of an extra-cardiovascular implantable cardioverter defibrillator system |
US10045710B2 (en) | 2016-03-30 | 2018-08-14 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10046167B2 (en) | 2015-02-09 | 2018-08-14 | Cardiac Pacemakers, Inc. | Implantable medical device with radiopaque ID tag |
US10050700B2 (en) | 2015-03-18 | 2018-08-14 | Cardiac Pacemakers, Inc. | Communications in a medical device system with temporal optimization |
US10058695B2 (en) | 2014-12-18 | 2018-08-28 | Medtronic, Inc. | Collapsible extravascular lead |
US10065041B2 (en) | 2015-10-08 | 2018-09-04 | Cardiac Pacemakers, Inc. | Devices and methods for adjusting pacing rates in an implantable medical device |
US10080891B2 (en) | 2015-12-03 | 2018-09-25 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system |
US10092760B2 (en) | 2015-09-11 | 2018-10-09 | Cardiac Pacemakers, Inc. | Arrhythmia detection and confirmation |
WO2018200228A1 (en) | 2017-04-25 | 2018-11-01 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
WO2018200227A1 (en) | 2017-04-26 | 2018-11-01 | Medtronic, Inc. | Cardiac event sensing in an implantable medical device |
US10137305B2 (en) | 2015-08-28 | 2018-11-27 | Cardiac Pacemakers, Inc. | Systems and methods for behaviorally responsive signal detection and therapy delivery |
US10143823B2 (en) | 2016-04-29 | 2018-12-04 | Medtronic, Inc. | Interventional medical systems and improved assemblies thereof and associated methods of use |
US10159842B2 (en) | 2015-08-28 | 2018-12-25 | Cardiac Pacemakers, Inc. | System and method for detecting tamponade |
US10183170B2 (en) | 2015-12-17 | 2019-01-22 | Cardiac Pacemakers, Inc. | Conducted communication in a medical device system |
WO2019036258A1 (en) | 2017-08-15 | 2019-02-21 | Medtronic, Inc. | Anti-tachycardia pacing control in an implantable medical device system |
WO2019036266A1 (en) | 2017-08-14 | 2019-02-21 | Medtronic, Inc. | Demand driven capacitor charging for cardiac pacing |
US10213125B2 (en) | 2015-01-23 | 2019-02-26 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10213610B2 (en) | 2015-03-18 | 2019-02-26 | Cardiac Pacemakers, Inc. | Communications in a medical device system with link quality assessment |
US10220213B2 (en) | 2015-02-06 | 2019-03-05 | Cardiac Pacemakers, Inc. | Systems and methods for safe delivery of electrical stimulation therapy |
US10226631B2 (en) | 2015-08-28 | 2019-03-12 | Cardiac Pacemakers, Inc. | Systems and methods for infarct detection |
US10245072B2 (en) | 2015-07-10 | 2019-04-02 | Medtronic, Inc. | Extravascular medical access tools having boring tip and methods of using such tools |
US10265098B2 (en) | 2015-10-29 | 2019-04-23 | Medtronic, Inc. | Multi-purpose medical tools and methods for gaining access to extravascular spaces in a patient |
WO2019083911A1 (en) | 2017-10-23 | 2019-05-02 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an implantable medical device |
US10300286B2 (en) | 2013-09-27 | 2019-05-28 | Medtronic, Inc. | Tools and assemblies thereof for implantable medical devices |
WO2019108765A1 (en) | 2017-11-29 | 2019-06-06 | Medtronic, Inc. | Tissue conduction communication using ramped drive signal |
WO2019108742A1 (en) | 2017-11-29 | 2019-06-06 | Medtronic, Inc. | Device and method to reduce artifact from tissue conduction communication transmission |
WO2019108787A1 (en) | 2017-11-29 | 2019-06-06 | Medtronic, Inc. | Tissue conduction communication between devices |
WO2019118807A1 (en) | 2017-12-15 | 2019-06-20 | Medtronic, Inc. | Device, system and method with adaptive timing for tissue conduction communication transmission |
WO2019118560A1 (en) | 2017-12-15 | 2019-06-20 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
US10328272B2 (en) | 2016-05-10 | 2019-06-25 | Cardiac Pacemakers, Inc. | Retrievability for implantable medical devices |
US10350423B2 (en) | 2016-02-04 | 2019-07-16 | Cardiac Pacemakers, Inc. | Delivery system with force sensor for leadless cardiac device |
US10357159B2 (en) | 2015-08-20 | 2019-07-23 | Cardiac Pacemakers, Inc | Systems and methods for communication between medical devices |
US10368769B2 (en) | 2016-07-27 | 2019-08-06 | Medtronic, Inc. | Automatic thresholds for atrial tachyarrhythmia detection in an implantable medical device |
US10391299B2 (en) | 2017-03-30 | 2019-08-27 | Medtronic, Inc. | Interventional medical systems for therapy delivery in extracardiovascular spaces and associated tools and methods |
US10391319B2 (en) | 2016-08-19 | 2019-08-27 | Cardiac Pacemakers, Inc. | Trans septal implantable medical device |
WO2019173739A1 (en) | 2018-03-09 | 2019-09-12 | Medtronic, Inc. | Ventricular assist device and cardiac electrical stimulation system for therapy control |
US10413733B2 (en) | 2016-10-27 | 2019-09-17 | Cardiac Pacemakers, Inc. | Implantable medical device with gyroscope |
US10426962B2 (en) | 2016-07-07 | 2019-10-01 | Cardiac Pacemakers, Inc. | Leadless pacemaker using pressure measurements for pacing capture verification |
US10434314B2 (en) | 2016-10-27 | 2019-10-08 | Cardiac Pacemakers, Inc. | Use of a separate device in managing the pace pulse energy of a cardiac pacemaker |
US10434317B2 (en) | 2016-10-31 | 2019-10-08 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
WO2019195425A1 (en) | 2018-04-03 | 2019-10-10 | Medtronic, Inc. | Feature based sensing for leadless pacing therapy |
WO2019209541A1 (en) | 2018-04-27 | 2019-10-31 | Medtronic, Inc. | Method and apparatus for delivering anti-tachycardia pacing |
WO2019210045A1 (en) | 2018-04-27 | 2019-10-31 | Medtronic, Inc. | Apparatus for charge balancing during delivery of electrical stimulation |
US10463305B2 (en) | 2016-10-27 | 2019-11-05 | Cardiac Pacemakers, Inc. | Multi-device cardiac resynchronization therapy with timing enhancements |
WO2019213190A1 (en) | 2018-05-03 | 2019-11-07 | Medtronic, Inc. | Mode of operation for an implantable cardiac rhythm management device co-implanted with a ventricular assist device |
US10512784B2 (en) | 2016-06-27 | 2019-12-24 | Cardiac Pacemakers, Inc. | Cardiac therapy system using subcutaneously sensed P-waves for resynchronization pacing management |
WO2020023839A1 (en) | 2018-07-27 | 2020-01-30 | Medtronic, Inc. | Fluid status detection from a cardiac electrical signal and an impedance signal |
WO2020028458A1 (en) | 2018-08-01 | 2020-02-06 | Medtronic, Inc. | Medical tools for and methods of gaining access to extravascular spaces |
US10561330B2 (en) | 2016-10-27 | 2020-02-18 | Cardiac Pacemakers, Inc. | Implantable medical device having a sense channel with performance adjustment |
US10583303B2 (en) | 2016-01-19 | 2020-03-10 | Cardiac Pacemakers, Inc. | Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device |
US10583301B2 (en) | 2016-11-08 | 2020-03-10 | Cardiac Pacemakers, Inc. | Implantable medical device for atrial deployment |
US10610694B2 (en) | 2017-01-20 | 2020-04-07 | Medtronic, Inc. | Implanted electrode configuration for physiological sensing and tissue conductance communication |
US10617874B2 (en) | 2016-10-31 | 2020-04-14 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
US10632313B2 (en) | 2016-11-09 | 2020-04-28 | Cardiac Pacemakers, Inc. | Systems, devices, and methods for setting cardiac pacing pulse parameters for a cardiac pacing device |
US10639486B2 (en) | 2016-11-21 | 2020-05-05 | Cardiac Pacemakers, Inc. | Implantable medical device with recharge coil |
US10668294B2 (en) | 2016-05-10 | 2020-06-02 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker configured for over the wire delivery |
US10675478B2 (en) | 2014-12-09 | 2020-06-09 | Medtronic, Inc. | Extravascular implantable electrical lead having undulating configuration |
US10688304B2 (en) | 2016-07-20 | 2020-06-23 | Cardiac Pacemakers, Inc. | Method and system for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US10722720B2 (en) | 2014-01-10 | 2020-07-28 | Cardiac Pacemakers, Inc. | Methods and systems for improved communication between medical devices |
US10737102B2 (en) | 2017-01-26 | 2020-08-11 | Cardiac Pacemakers, Inc. | Leadless implantable device with detachable fixation |
US10758737B2 (en) | 2016-09-21 | 2020-09-01 | Cardiac Pacemakers, Inc. | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter |
US10758724B2 (en) | 2016-10-27 | 2020-09-01 | Cardiac Pacemakers, Inc. | Implantable medical device delivery system with integrated sensor |
US10765871B2 (en) | 2016-10-27 | 2020-09-08 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
US10780278B2 (en) | 2016-08-24 | 2020-09-22 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using P-wave to pace timing |
US10821288B2 (en) | 2017-04-03 | 2020-11-03 | Cardiac Pacemakers, Inc. | Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate |
US10835753B2 (en) | 2017-01-26 | 2020-11-17 | Cardiac Pacemakers, Inc. | Intra-body device communication with redundant message transmission |
US10870008B2 (en) | 2016-08-24 | 2020-12-22 | Cardiac Pacemakers, Inc. | Cardiac resynchronization using fusion promotion for timing management |
US10874861B2 (en) | 2018-01-04 | 2020-12-29 | Cardiac Pacemakers, Inc. | Dual chamber pacing without beat-to-beat communication |
US10881869B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Wireless re-charge of an implantable medical device |
US10881863B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker with multimode communication |
US10894163B2 (en) | 2016-11-21 | 2021-01-19 | Cardiac Pacemakers, Inc. | LCP based predictive timing for cardiac resynchronization |
US10905886B2 (en) | 2015-12-28 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device for deployment across the atrioventricular septum |
US10905889B2 (en) | 2016-09-21 | 2021-02-02 | Cardiac Pacemakers, Inc. | Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery |
US10905872B2 (en) | 2017-04-03 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device with a movable electrode biased toward an extended position |
US10918875B2 (en) | 2017-08-18 | 2021-02-16 | Cardiac Pacemakers, Inc. | Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator |
US10994145B2 (en) | 2016-09-21 | 2021-05-04 | Cardiac Pacemakers, Inc. | Implantable cardiac monitor |
US11052258B2 (en) | 2017-12-01 | 2021-07-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker |
US11058880B2 (en) | 2018-03-23 | 2021-07-13 | Medtronic, Inc. | VFA cardiac therapy for tachycardia |
US11065459B2 (en) | 2017-08-18 | 2021-07-20 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
US11071870B2 (en) | 2017-12-01 | 2021-07-27 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker |
US11110279B2 (en) | 2017-11-29 | 2021-09-07 | Medtronic, Inc. | Signal transmission optimization for tissue conduction communication |
US11116988B2 (en) | 2016-03-31 | 2021-09-14 | Cardiac Pacemakers, Inc. | Implantable medical device with rechargeable battery |
US11147979B2 (en) | 2016-11-21 | 2021-10-19 | Cardiac Pacemakers, Inc. | Implantable medical device with a magnetically permeable housing and an inductive coil disposed about the housing |
US11185703B2 (en) | 2017-11-07 | 2021-11-30 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker for bundle of his pacing |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US11207532B2 (en) | 2017-01-04 | 2021-12-28 | Cardiac Pacemakers, Inc. | Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system |
US11213676B2 (en) | 2019-04-01 | 2022-01-04 | Medtronic, Inc. | Delivery systems for VfA cardiac therapy |
US11235159B2 (en) | 2018-03-23 | 2022-02-01 | Medtronic, Inc. | VFA cardiac resynchronization therapy |
US11235163B2 (en) | 2017-09-20 | 2022-02-01 | Cardiac Pacemakers, Inc. | Implantable medical device with multiple modes of operation |
US11235161B2 (en) | 2018-09-26 | 2022-02-01 | Medtronic, Inc. | Capture in ventricle-from-atrium cardiac therapy |
US11260216B2 (en) | 2017-12-01 | 2022-03-01 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker |
US11285326B2 (en) | 2015-03-04 | 2022-03-29 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US11305127B2 (en) | 2019-08-26 | 2022-04-19 | Medtronic Inc. | VfA delivery and implant region detection |
US11400296B2 (en) | 2018-03-23 | 2022-08-02 | Medtronic, Inc. | AV synchronous VfA cardiac therapy |
US11529523B2 (en) | 2018-01-04 | 2022-12-20 | Cardiac Pacemakers, Inc. | Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone |
US11679265B2 (en) | 2019-02-14 | 2023-06-20 | Medtronic, Inc. | Lead-in-lead systems and methods for cardiac therapy |
US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
US11712188B2 (en) | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
US11813464B2 (en) | 2020-07-31 | 2023-11-14 | Medtronic, Inc. | Cardiac conduction system evaluation |
US11813466B2 (en) | 2020-01-27 | 2023-11-14 | Medtronic, Inc. | Atrioventricular nodal stimulation |
US11813463B2 (en) | 2017-12-01 | 2023-11-14 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker with reversionary behavior |
US11911168B2 (en) | 2020-04-03 | 2024-02-27 | Medtronic, Inc. | Cardiac conduction system therapy benefit determination |
US11951313B2 (en) | 2018-11-17 | 2024-04-09 | Medtronic, Inc. | VFA delivery systems and methods |
US12097377B2 (en) | 2021-03-09 | 2024-09-24 | Medtronic, Inc. | Asystole detection and response in an implantable cardioverter defibrillator |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5563652B2 (en) | 2009-03-17 | 2014-07-30 | カーディオスライヴ インコーポレイテッド | External defibrillator |
JP5736464B2 (en) * | 2010-11-23 | 2015-06-17 | カーディアック ペースメイカーズ, インコーポレイテッド | Cardiac anodic electrical stimulation detection |
US10279189B2 (en) | 2013-06-14 | 2019-05-07 | Cardiothrive, Inc. | Wearable multiphasic cardioverter defibrillator system and method |
US9616243B2 (en) | 2013-06-14 | 2017-04-11 | Cardiothrive, Inc. | Dynamically adjustable multiphasic defibrillator pulse system and method |
US9833630B2 (en) | 2013-06-14 | 2017-12-05 | Cardiothrive, Inc. | Biphasic or multiphasic pulse waveform and method |
US10149973B2 (en) | 2013-06-14 | 2018-12-11 | Cardiothrive, Inc. | Multipart non-uniform patient contact interface and method of use |
EP3188793B1 (en) | 2014-09-04 | 2020-01-01 | Atacor Medical, Inc. | Receptacle for pacemaker lead |
US10743960B2 (en) | 2014-09-04 | 2020-08-18 | AtaCor Medical, Inc. | Cardiac arrhythmia treatment devices and delivery |
US10328268B2 (en) | 2014-09-04 | 2019-06-25 | AtaCor Medical, Inc. | Cardiac pacing |
US9636512B2 (en) | 2014-11-05 | 2017-05-02 | Medtronic, Inc. | Implantable cardioverter-defibrillator (ICD) system having multiple common polarity extravascular defibrillation electrodes |
US11097109B2 (en) | 2014-11-24 | 2021-08-24 | AtaCor Medical, Inc. | Cardiac pacing sensing and control |
US10046168B2 (en) | 2015-12-03 | 2018-08-14 | Medtronic, Inc. | Tachyarrhythmia induction by an extra-cardiovascular implantable cardioverter defibrillator |
US11291833B2 (en) * | 2018-05-09 | 2022-04-05 | Medtronic, Inc. | Bonding strip for fixing an electrode coil to a lead body |
US11096757B2 (en) * | 2018-06-28 | 2021-08-24 | Medtronic, Inc. | Implantable medical lead indicators |
US11951319B2 (en) | 2018-08-07 | 2024-04-09 | Pacesetter, Inc. | Systems and methods for applying anti-tachycardia pacing using subcutaneous implantable cardioverter-defibrillators |
EP3976167A1 (en) | 2019-05-29 | 2022-04-06 | Atacor Medical, Inc. | Implantable electrical leads and associated delivery systems |
EP3760114B1 (en) | 2019-07-05 | 2024-01-24 | Sorin CRM SAS | Subcutaneous implantable medical device for processing signals from a subcutaneous implantable medical device |
EP3760277B1 (en) | 2019-07-05 | 2022-09-21 | Sorin CRM SAS | Subcutaneous implantable cardiac defibrillation system |
US11666771B2 (en) | 2020-05-29 | 2023-06-06 | AtaCor Medical, Inc. | Implantable electrical leads and associated delivery systems |
US11779770B2 (en) | 2020-07-24 | 2023-10-10 | Biosense Webster (Israel) Ltd. | Universal pacing of a catheter |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6430449B1 (en) * | 1998-03-19 | 2002-08-06 | Cardiac Pacemackers, Inc. | Catheter for treating supraventricular tachyarrhythmias |
US20100121421A1 (en) * | 2008-11-07 | 2010-05-13 | Jeffrey B Duncan | Implantable lead |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2922024A (en) | 1954-05-04 | 1960-01-19 | British Oxygen Co Ltd | Electric arc welding |
US3496932A (en) | 1967-12-22 | 1970-02-24 | Gen Motors Corp | Method and apparatus for substernal cardiac massage |
US4030509A (en) | 1975-09-30 | 1977-06-21 | Mieczyslaw Mirowski | Implantable electrodes for accomplishing ventricular defibrillation and pacing and method of electrode implantation and utilization |
US4161952A (en) | 1977-11-01 | 1979-07-24 | Mieczyslaw Mirowski | Wound wire catheter cardioverting electrode |
US4374527A (en) | 1978-07-19 | 1983-02-22 | Medtronic, Inc. | Body stimulation lead |
US4379462A (en) | 1980-10-29 | 1983-04-12 | Neuromed, Inc. | Multi-electrode catheter assembly for spinal cord stimulation |
US4355646A (en) | 1980-11-26 | 1982-10-26 | Medtronic, Inc. | Transvenous defibrillating lead |
US4765341A (en) | 1981-06-22 | 1988-08-23 | Mieczyslaw Mirowski | Cardiac electrode with attachment fin |
US4628934A (en) | 1984-08-07 | 1986-12-16 | Cordis Corporation | Method and means of electrode selection for pacemaker with multielectrode leads |
US4922927A (en) | 1987-12-30 | 1990-05-08 | Intermedics, Inc. | Transvenous defibrillating and pacing lead |
US4947866A (en) | 1988-02-16 | 1990-08-14 | Medtronic, Inc. | Medical electrical lead |
US5176135A (en) | 1989-09-06 | 1993-01-05 | Ventritex, Inc. | Implantable defibrillation electrode system |
US4991603A (en) | 1989-10-30 | 1991-02-12 | Siemens-Pacesetter, Inc. | Transvenously placed defibrillation leads via an inferior vena cava access site and method of use |
US5269319A (en) | 1989-12-08 | 1993-12-14 | Cardiac Pacemakers, Inc. | Unitary intravascular defibrillating catheter with bipolar sensing |
US5203348A (en) | 1990-06-06 | 1993-04-20 | Cardiac Pacemakers, Inc. | Subcutaneous defibrillation electrodes |
US5121754A (en) | 1990-08-21 | 1992-06-16 | Medtronic, Inc. | Lateral displacement percutaneously inserted epidural lead |
US5282845A (en) | 1990-10-01 | 1994-02-01 | Ventritex, Inc. | Multiple electrode deployable lead |
US5105826A (en) | 1990-10-26 | 1992-04-21 | Medtronic, Inc. | Implantable defibrillation electrode and method of manufacture |
US5174288A (en) | 1990-11-30 | 1992-12-29 | Medtronic, Inc. | Method and apparatus for cardiac defibrillation |
CA2108012A1 (en) | 1991-04-10 | 1992-10-11 | Leo Rubin | Defibrillator and demand pacer catheter and method |
US5496362A (en) | 1992-11-24 | 1996-03-05 | Cardiac Pacemakers, Inc. | Implantable conformal coil patch electrode with multiple conductive elements for cardioversion and defibrillation |
US5325870A (en) | 1992-12-16 | 1994-07-05 | Angeion Corporation | Multiplexed defibrillation electrode apparatus |
US5387233A (en) | 1993-01-11 | 1995-02-07 | Incontrol, Inc. | Intravenous cardiac lead with improved fixation and method |
US5336253A (en) * | 1993-02-23 | 1994-08-09 | Medtronic, Inc. | Pacing and cardioversion lead systems with shared lead conductors |
US5676698A (en) | 1993-09-07 | 1997-10-14 | Datascope Investment Corp. | Soft tissue implant |
US5456706A (en) | 1994-01-04 | 1995-10-10 | Ventritex, Inc. | Cardiac defibrillation lead having defibrillation and atrial sensing electrodes |
US5522874A (en) | 1994-07-28 | 1996-06-04 | Gates; James T. | Medical lead having segmented electrode |
JPH08139632A (en) | 1994-11-15 | 1996-05-31 | Uniden Corp | Narrow band communication equipment |
US5534022A (en) | 1994-11-22 | 1996-07-09 | Ventritex, Inc. | Lead having an integrated defibrillation/sensing electrode |
US5545183A (en) | 1994-12-07 | 1996-08-13 | Ventritex, Inc. | Method and apparatus for delivering defibrillation therapy through a sensing electrode |
US5654030A (en) | 1995-02-07 | 1997-08-05 | Intermedics, Inc. | Method of making implantable stimulation electrodes |
US5683443A (en) | 1995-02-07 | 1997-11-04 | Intermedics, Inc. | Implantable stimulation electrodes with non-native metal oxide coating mixtures |
US5833714A (en) | 1996-01-18 | 1998-11-10 | Loeb; Gerald E. | Cochlear electrode array employing tantalum metal |
US5772693A (en) | 1996-02-09 | 1998-06-30 | Cardiac Control Systems, Inc. | Single preformed catheter configuration for a dual-chamber pacemaker system |
US5709644A (en) | 1996-06-14 | 1998-01-20 | Pacesetter, Inc. | Implantable suture sleeve modified to reduce tissue ingrowth |
US5800465A (en) | 1996-06-18 | 1998-09-01 | Medtronic, Inc. | System and method for multisite steering of cardiac stimuli |
US5810887A (en) | 1996-08-23 | 1998-09-22 | Rhythm Technologies, Inc. | Temporary catheter |
US5853426A (en) | 1997-06-02 | 1998-12-29 | Pacesetter, Inc. | Method and apparatus for delivering atrial defibrillaton therapy with improved effectiveness |
US5922014A (en) | 1997-09-02 | 1999-07-13 | Medtronic, Inc. | Single pass lead and method of use |
US5871531A (en) | 1997-09-25 | 1999-02-16 | Medtronic, Inc. | Medical electrical lead having tapered spiral fixation |
US5849031A (en) | 1997-12-16 | 1998-12-15 | Medtronic, Inc. | Method and apparatus for termination of tachyarrhythmias |
US6345198B1 (en) | 1998-01-23 | 2002-02-05 | Pacesetter, Inc. | Implantable stimulation system for providing dual bipolar sensing using an electrode positioned in proximity to the tricuspid valve and programmable polarity |
US5925073A (en) | 1998-02-23 | 1999-07-20 | Cardiac Pacemakers, Inc. | Intravenous cardiac lead with wave shaped fixation segment |
US6256541B1 (en) * | 1998-04-17 | 2001-07-03 | Cardiac Pacemakers, Inc. | Endocardial lead having defibrillation and sensing electrodes with septal anchoring |
US6066165A (en) | 1998-04-30 | 2000-05-23 | Racz; Gabor B | Medical lead with sigma feature |
US6327498B1 (en) | 1998-10-07 | 2001-12-04 | Pacesetter, Inc. | Implantable stimulation lead for use with an ICD device having automatic capture pacing features |
US7313444B2 (en) | 1998-11-20 | 2007-12-25 | Pacesetter, Inc. | Self-anchoring coronary sinus lead |
US6321123B1 (en) | 1999-03-08 | 2001-11-20 | Medtronic Inc. | J-shaped coronary sinus lead |
US6702811B2 (en) | 1999-04-05 | 2004-03-09 | Medtronic, Inc. | Ablation catheter assembly with radially decreasing helix and method of use |
US6584362B1 (en) | 2000-08-30 | 2003-06-24 | Cardiac Pacemakers, Inc. | Leads for pacing and/or sensing the heart from within the coronary veins |
US6952610B2 (en) * | 2000-09-18 | 2005-10-04 | Cameron Health, Inc. | Current waveforms for anti-tachycardia pacing for a subcutaneous implantable cardioverter- defibrillator |
US20020035377A1 (en) | 2000-09-18 | 2002-03-21 | Cameron Health, Inc. | Subcutaneous electrode for transthoracic conduction with insertion tool |
US6988003B2 (en) | 2000-09-18 | 2006-01-17 | Cameron Health, Inc. | Implantable cardioverter-defibrillator having two spaced apart shocking electrodes on housing |
US6721597B1 (en) * | 2000-09-18 | 2004-04-13 | Cameron Health, Inc. | Subcutaneous only implantable cardioverter defibrillator and optional pacer |
US6735472B2 (en) | 2001-01-26 | 2004-05-11 | Pacesetter, Inc. | Method of defibrillating a heart with electrode configurations including a left ventricular defibrillation electrode |
US6658289B2 (en) | 2001-01-26 | 2003-12-02 | Pacesetter, Inc. | Universal pacing and defibrillation system |
US6650945B2 (en) * | 2001-01-26 | 2003-11-18 | Pacesetter, Inc. | Implantable cardiac coronary sinus lead having a defibrillation electrode of split configuration and method of manufacture |
US20030013986A1 (en) | 2001-07-12 | 2003-01-16 | Vahid Saadat | Device for sensing temperature profile of a hollow body organ |
DE10142834A1 (en) | 2001-08-23 | 2003-03-06 | Biotronik Mess & Therapieg | Single electrode probe for pacemaker systems |
US6721598B1 (en) | 2001-08-31 | 2004-04-13 | Pacesetter, Inc. | Coronary sinus cardiac lead for stimulating and sensing in the right and left heart and system |
US20030105501A1 (en) | 2001-12-03 | 2003-06-05 | Warman Eduardo N. | Shaped lead with electrodes |
SE525091C2 (en) | 2003-04-16 | 2004-11-30 | Alfa Laval Corp Ab | An apparatus for purifying a gas |
US8017178B2 (en) | 2003-12-16 | 2011-09-13 | Cardiac Pacemakers, Inc. | Coatings for implantable electrodes |
US7136702B2 (en) * | 2004-03-19 | 2006-11-14 | Medtronic, Inc. | Method and apparatus for delivering multi-directional defibrillation waveforms |
US20060020316A1 (en) | 2004-06-03 | 2006-01-26 | Medtronic, Inc. | Implantable cardioversion and defibrillation system including intramural myocardial elecrtode |
US20060041295A1 (en) | 2004-08-17 | 2006-02-23 | Osypka Thomas P | Positive fixation percutaneous epidural neurostimulation lead |
JP2008534196A (en) | 2005-04-06 | 2008-08-28 | シャルマー,フリーデリーケ | Implantable electromedical or extracorporeally applicable device for organ treatment and organ monitoring and method for therapeutic organ treatment |
US7684864B2 (en) | 2005-04-28 | 2010-03-23 | Medtronic, Inc. | Subcutaneous cardioverter-defibrillator |
US20060247753A1 (en) | 2005-04-29 | 2006-11-02 | Wenger William K | Subcutaneous lead fixation mechanisms |
EP1898999A4 (en) | 2005-07-01 | 2011-10-19 | Proteus Biomedical Inc | Deployable epicardial electrode and sensor array |
US8160684B2 (en) * | 2006-03-29 | 2012-04-17 | Medtronic, Inc. | Method and apparatus for detecting arrhythmias in a medical device |
US20070250142A1 (en) | 2006-03-30 | 2007-10-25 | Francis Richard W | Atomic Layer Deposition Coatings for Implantable Medical Devices |
US7899555B2 (en) | 2006-04-11 | 2011-03-01 | Pacesetter, Inc. | Intrapericardial lead |
US20080046058A1 (en) | 2006-04-28 | 2008-02-21 | Cross Thomas E | Methods for customizing implantable medical lead assemblies with improved flexibility and extensibility |
US7917216B1 (en) | 2006-07-19 | 2011-03-29 | Pacesetter, Inc. | Multi-site pacing for atrial tachyarrhythmias |
US20080046059A1 (en) | 2006-08-04 | 2008-02-21 | Zarembo Paul E | Lead including a heat fused or formed lead body |
US7668601B2 (en) | 2007-04-26 | 2010-02-23 | Medtronic, Inc. | Implantable medical lead with multiple electrode configurations |
WO2008134651A2 (en) | 2007-04-27 | 2008-11-06 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Apparatus and method for positioning and retention of catheter |
WO2009006331A1 (en) | 2007-06-29 | 2009-01-08 | Action Medical, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
EP2276399B1 (en) | 2008-03-25 | 2012-05-16 | Medtronic, Inc. | Robust high power and low power cardiac leads having integrated sensors |
US8874237B2 (en) | 2008-04-16 | 2014-10-28 | Medtronic, Inc. | Delivery catheter including side port and electrodes |
US20090287266A1 (en) | 2008-05-13 | 2009-11-19 | Mark Zdeblick | High-voltage tolerant multiplex multi-electrode stimulation systems and methods for using the same |
US8655458B2 (en) | 2008-09-05 | 2014-02-18 | Cardiac Pacemakers, Inc. | Conformal electrodes for shaped medical device lead body segments |
US20100114195A1 (en) * | 2008-10-31 | 2010-05-06 | Medtronic, Inc. | Implantable medical device including extravascular cardiac stimulation and neurostimulation capabilities |
US8364281B2 (en) * | 2008-11-07 | 2013-01-29 | W. L. Gore & Associates, Inc. | Implantable lead |
WO2010088539A1 (en) | 2009-01-30 | 2010-08-05 | Medtronic, Inc. | Detecting and treating electromechanical dissociation of the heart |
US9468754B2 (en) | 2009-05-29 | 2016-10-18 | Medtronic, Inc. | Leads for selective sensing and virtual electrodes |
US9974944B2 (en) | 2010-07-29 | 2018-05-22 | Cameron Health, Inc. | Subcutaneous leads and methods of implant and explant |
US9050456B2 (en) | 2011-07-21 | 2015-06-09 | Biotronik Se & Co. Kg | Unipolar multipurpose electrode line and stimulation and defibrillation assembly |
US9999763B2 (en) | 2012-06-13 | 2018-06-19 | Mainstay Medical Limited | Apparatus and methods for anchoring electrode leads adjacent to nervous tissue |
US9370311B2 (en) | 2012-08-17 | 2016-06-21 | Medtronic Ablation Frontiers Llc | Electrophysiology catheter design |
US10471267B2 (en) | 2013-05-06 | 2019-11-12 | Medtronic, Inc. | Implantable cardioverter-defibrillator (ICD) system including substernal lead |
US10556117B2 (en) | 2013-05-06 | 2020-02-11 | Medtronic, Inc. | Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead |
US20150142010A1 (en) | 2013-11-21 | 2015-05-21 | Pacesetter, Inc. | Neurostimulation leads having two-dimensional arrays |
US20150306375A1 (en) | 2014-04-25 | 2015-10-29 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
WO2016094470A1 (en) | 2014-12-09 | 2016-06-16 | Medtronic, Inc. | Extravascular implantable electrical lead having undulating configuration |
US11027132B2 (en) | 2016-03-16 | 2021-06-08 | Medtronic, Inc. | Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system |
-
2014
- 2014-10-21 US US14/519,436 patent/US20150306375A1/en not_active Abandoned
-
2015
- 2015-04-24 WO PCT/US2015/027478 patent/WO2015164715A1/en active Application Filing
- 2015-04-24 EP EP23164085.5A patent/EP4223357B1/en active Active
- 2015-04-24 CN CN201580032591.3A patent/CN106413809B/en active Active
- 2015-04-24 US US14/695,255 patent/US9855414B2/en active Active
- 2015-04-24 EP EP15721469.3A patent/EP3134169B1/en active Active
-
2018
- 2018-01-02 US US15/860,310 patent/US10137295B2/en active Active
- 2018-11-27 US US16/200,846 patent/US10661073B2/en active Active
-
2020
- 2020-05-20 US US16/879,281 patent/US11534603B2/en active Active
-
2022
- 2022-12-07 US US18/062,714 patent/US20230109342A1/en active Pending
-
2023
- 2023-06-08 US US18/331,793 patent/US12083333B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6430449B1 (en) * | 1998-03-19 | 2002-08-06 | Cardiac Pacemackers, Inc. | Catheter for treating supraventricular tachyarrhythmias |
US20100121421A1 (en) * | 2008-11-07 | 2010-05-13 | Jeffrey B Duncan | Implantable lead |
Cited By (230)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10300286B2 (en) | 2013-09-27 | 2019-05-28 | Medtronic, Inc. | Tools and assemblies thereof for implantable medical devices |
US9526522B2 (en) | 2013-09-27 | 2016-12-27 | Medtronic, Inc. | Interventional medical systems, tools, and assemblies |
US11110278B2 (en) | 2013-09-27 | 2021-09-07 | Medtronic, Inc. | Tools and assemblies thereof for implantable medical devices |
US10722720B2 (en) | 2014-01-10 | 2020-07-28 | Cardiac Pacemakers, Inc. | Methods and systems for improved communication between medical devices |
US9592391B2 (en) | 2014-01-10 | 2017-03-14 | Cardiac Pacemakers, Inc. | Systems and methods for detecting cardiac arrhythmias |
US12083333B2 (en) | 2014-04-25 | 2024-09-10 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US10137295B2 (en) | 2014-04-25 | 2018-11-27 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US11534603B2 (en) | 2014-04-25 | 2022-12-27 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US10661073B2 (en) | 2014-04-25 | 2020-05-26 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US9855414B2 (en) | 2014-04-25 | 2018-01-02 | Medtronic, Inc. | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability |
US9526909B2 (en) | 2014-08-28 | 2016-12-27 | Cardiac Pacemakers, Inc. | Medical device with triggered blanking period |
US11813447B2 (en) | 2014-12-09 | 2023-11-14 | Medtronic, Inc. | Extravascular implantable electrical lead having undulating configuration |
US10675478B2 (en) | 2014-12-09 | 2020-06-09 | Medtronic, Inc. | Extravascular implantable electrical lead having undulating configuration |
US10058695B2 (en) | 2014-12-18 | 2018-08-28 | Medtronic, Inc. | Collapsible extravascular lead |
US9675261B2 (en) | 2015-01-23 | 2017-06-13 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10213125B2 (en) | 2015-01-23 | 2019-02-26 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10004418B2 (en) | 2015-01-23 | 2018-06-26 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US11224751B2 (en) | 2015-02-06 | 2022-01-18 | Cardiac Pacemakers, Inc. | Systems and methods for safe delivery of electrical stimulation therapy |
US11020595B2 (en) | 2015-02-06 | 2021-06-01 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US9669230B2 (en) | 2015-02-06 | 2017-06-06 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US10220213B2 (en) | 2015-02-06 | 2019-03-05 | Cardiac Pacemakers, Inc. | Systems and methods for safe delivery of electrical stimulation therapy |
US10238882B2 (en) | 2015-02-06 | 2019-03-26 | Cardiac Pacemakers | Systems and methods for treating cardiac arrhythmias |
US11020600B2 (en) | 2015-02-09 | 2021-06-01 | Cardiac Pacemakers, Inc. | Implantable medical device with radiopaque ID tag |
US10046167B2 (en) | 2015-02-09 | 2018-08-14 | Cardiac Pacemakers, Inc. | Implantable medical device with radiopaque ID tag |
US9675269B2 (en) | 2015-02-18 | 2017-06-13 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US9936890B2 (en) | 2015-02-18 | 2018-04-10 | Medtronic, Inc. | Method and apparatus for adjusting a threshold during atrial arrhythmia episode detection in an implantable medical device |
US10492706B2 (en) | 2015-02-18 | 2019-12-03 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US9962102B2 (en) | 2015-02-18 | 2018-05-08 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US9901276B2 (en) | 2015-02-18 | 2018-02-27 | Medtronic, Inc. | Method and apparatus for identifying sick sinus syndrome in an implantable cardiac monitoring device |
US11517242B2 (en) | 2015-02-18 | 2022-12-06 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US9486155B2 (en) | 2015-02-18 | 2016-11-08 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US9603543B2 (en) | 2015-02-18 | 2017-03-28 | Medtronic, Inc. | Method and apparatus for atrial arrhythmia episode detection |
US11285326B2 (en) | 2015-03-04 | 2022-03-29 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US11476927B2 (en) | 2015-03-18 | 2022-10-18 | Cardiac Pacemakers, Inc. | Communications in a medical device system with temporal optimization |
US10213610B2 (en) | 2015-03-18 | 2019-02-26 | Cardiac Pacemakers, Inc. | Communications in a medical device system with link quality assessment |
US10946202B2 (en) | 2015-03-18 | 2021-03-16 | Cardiac Pacemakers, Inc. | Communications in a medical device system with link quality assessment |
US10050700B2 (en) | 2015-03-18 | 2018-08-14 | Cardiac Pacemakers, Inc. | Communications in a medical device system with temporal optimization |
US10695089B2 (en) | 2015-07-10 | 2020-06-30 | Medtronic, Inc. | Medical tools and methods for gaining access to extravascular spaces |
WO2017011280A1 (en) | 2015-07-10 | 2017-01-19 | Medtronic, Inc. | Medical tools for gaining access to extravascular spaces |
US11090081B2 (en) | 2015-07-10 | 2021-08-17 | Medtronic, Inc. | Extravascular medical access tools having boring tip and methods of using such tools |
US10245072B2 (en) | 2015-07-10 | 2019-04-02 | Medtronic, Inc. | Extravascular medical access tools having boring tip and methods of using such tools |
US11844547B2 (en) | 2015-07-10 | 2023-12-19 | Medtronic, Inc. | Medical tools and methods for gaining access to extravascular spaces |
US9853743B2 (en) | 2015-08-20 | 2017-12-26 | Cardiac Pacemakers, Inc. | Systems and methods for communication between medical devices |
US10357159B2 (en) | 2015-08-20 | 2019-07-23 | Cardiac Pacemakers, Inc | Systems and methods for communication between medical devices |
US10709892B2 (en) | 2015-08-27 | 2020-07-14 | Cardiac Pacemakers, Inc. | Temporal configuration of a motion sensor in an implantable medical device |
US9956414B2 (en) | 2015-08-27 | 2018-05-01 | Cardiac Pacemakers, Inc. | Temporal configuration of a motion sensor in an implantable medical device |
US9968787B2 (en) | 2015-08-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Spatial configuration of a motion sensor in an implantable medical device |
US10226631B2 (en) | 2015-08-28 | 2019-03-12 | Cardiac Pacemakers, Inc. | Systems and methods for infarct detection |
US10137305B2 (en) | 2015-08-28 | 2018-11-27 | Cardiac Pacemakers, Inc. | Systems and methods for behaviorally responsive signal detection and therapy delivery |
US10159842B2 (en) | 2015-08-28 | 2018-12-25 | Cardiac Pacemakers, Inc. | System and method for detecting tamponade |
US10589101B2 (en) | 2015-08-28 | 2020-03-17 | Cardiac Pacemakers, Inc. | System and method for detecting tamponade |
US10092760B2 (en) | 2015-09-11 | 2018-10-09 | Cardiac Pacemakers, Inc. | Arrhythmia detection and confirmation |
US10065041B2 (en) | 2015-10-08 | 2018-09-04 | Cardiac Pacemakers, Inc. | Devices and methods for adjusting pacing rates in an implantable medical device |
US10265098B2 (en) | 2015-10-29 | 2019-04-23 | Medtronic, Inc. | Multi-purpose medical tools and methods for gaining access to extravascular spaces in a patient |
US10080891B2 (en) | 2015-12-03 | 2018-09-25 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system |
US11672988B2 (en) | 2015-12-03 | 2023-06-13 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system |
US10449362B2 (en) | 2015-12-03 | 2019-10-22 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system for delivering composite pacing pulses |
US11406838B2 (en) | 2015-12-03 | 2022-08-09 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system for delivering composite pacing pulses |
US12059568B2 (en) | 2015-12-03 | 2024-08-13 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system |
US11065453B2 (en) | 2015-12-03 | 2021-07-20 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system |
US11883677B2 (en) | 2015-12-03 | 2024-01-30 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system for delivering composite pacing pulses |
WO2017096257A1 (en) | 2015-12-03 | 2017-06-08 | Medtronic, Inc. | Extra-cardiovascular cardiac pacing system for delivering composite pacing pulses |
WO2017096181A1 (en) | 2015-12-03 | 2017-06-08 | Medtronic, Inc. | Extra-cardiovascular pacing using high-voltage therapy circuitry of an implantable cardioverter defibrillator |
EP4112119A1 (en) | 2015-12-03 | 2023-01-04 | Medtronic, Inc. | Extra-cardiovascular pacing by an implantable cardioverter defibrillator |
US10933245B2 (en) | 2015-12-17 | 2021-03-02 | Cardiac Pacemakers, Inc. | Conducted communication in a medical device system |
US10183170B2 (en) | 2015-12-17 | 2019-01-22 | Cardiac Pacemakers, Inc. | Conducted communication in a medical device system |
US10905886B2 (en) | 2015-12-28 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device for deployment across the atrioventricular septum |
US10583303B2 (en) | 2016-01-19 | 2020-03-10 | Cardiac Pacemakers, Inc. | Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device |
US10350423B2 (en) | 2016-02-04 | 2019-07-16 | Cardiac Pacemakers, Inc. | Delivery system with force sensor for leadless cardiac device |
US11752344B2 (en) | 2016-03-16 | 2023-09-12 | Medtronic, Inc. | Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system |
US11027132B2 (en) | 2016-03-16 | 2021-06-08 | Medtronic, Inc. | Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system |
WO2017160507A1 (en) | 2016-03-16 | 2017-09-21 | Medtronic, Inc. | Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system |
WO2017172272A1 (en) | 2016-03-30 | 2017-10-05 | Medtronic, Inc. | Medical system for detecting an atrial tachyarrhythmia through classification based on heart rate variability |
US10039469B2 (en) | 2016-03-30 | 2018-08-07 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10045710B2 (en) | 2016-03-30 | 2018-08-14 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US10575748B2 (en) | 2016-03-30 | 2020-03-03 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US11576607B2 (en) | 2016-03-30 | 2023-02-14 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US11826153B2 (en) | 2016-03-30 | 2023-11-28 | Medtronic, Inc. | Atrial arrhythmia episode detection in a cardiac medical device |
US11116988B2 (en) | 2016-03-31 | 2021-09-14 | Cardiac Pacemakers, Inc. | Implantable medical device with rechargeable battery |
EP4257047A2 (en) | 2016-04-27 | 2023-10-11 | Medtronic, Inc. | System for sensing and detection in an extra-cardiovascular implantable cardioverter defibrillator |
EP3812005A1 (en) | 2016-04-27 | 2021-04-28 | Medtronic, Inc | System for sensing and detection in an extra-cardiovascular implantable cardioverter defibrillator |
US9956423B2 (en) | 2016-04-27 | 2018-05-01 | Medtronic, Inc. | System and method for sensing and detection in an extra-cardiovascular implantable cardioverter defibrillator |
WO2017189144A1 (en) | 2016-04-27 | 2017-11-02 | Medtronic, Inc. | System and method for sensing and detection in an extra-cardiovascular implantable cardioverter defibrillator |
US11413470B2 (en) | 2016-04-27 | 2022-08-16 | Medtronic, Inc. | System and method for sensing and detection in an extra-cardiovascular implantable cardioverter defibrtillator |
US10507332B2 (en) | 2016-04-27 | 2019-12-17 | Medtronic, Inc. | System and method for sensing and detection in an extra-cardiovascular implantable cardioverter defibrillator |
EP3812006A1 (en) | 2016-04-28 | 2021-04-28 | Medtronic, Inc. | Implantable cardioverter defibrillator with asystole detection and pacing response |
US10130824B2 (en) | 2016-04-28 | 2018-11-20 | Medtronic, Inc. | Asystole detection and response in an implantable cardioverter defibrillator |
WO2017189558A1 (en) | 2016-04-28 | 2017-11-02 | Medtronic, Inc. | Implantable cardioverter defibrillator with asystole detection and pacing response |
US10940325B2 (en) | 2016-04-28 | 2021-03-09 | Medtronic, Inc. | Asystole detection and response in an implantable cardioverter defibrillator |
US10143823B2 (en) | 2016-04-29 | 2018-12-04 | Medtronic, Inc. | Interventional medical systems and improved assemblies thereof and associated methods of use |
EP3701862A1 (en) | 2016-04-29 | 2020-09-02 | Medtronic Inc. | Multi-threshold sensing of cardiac electrical signals in an extracardiovascular implantable cardioverter defibrillator |
US10493291B2 (en) | 2016-04-29 | 2019-12-03 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an extracardiovascular implantable cardioverter defibrillator |
US11413469B2 (en) | 2016-04-29 | 2022-08-16 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an extracardiovascular implantable cardioverter defibrillator |
WO2017189802A1 (en) | 2016-04-29 | 2017-11-02 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an extracardiovascular implantable cardioverter defibrillator |
US10252071B2 (en) | 2016-04-29 | 2019-04-09 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an extracardiovascular implantable cardioverter defibrillator |
US10668294B2 (en) | 2016-05-10 | 2020-06-02 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker configured for over the wire delivery |
US10328272B2 (en) | 2016-05-10 | 2019-06-25 | Cardiac Pacemakers, Inc. | Retrievability for implantable medical devices |
US12011608B2 (en) | 2016-06-08 | 2024-06-18 | Medtronic, Inc. | System and method for identifying and responding to P-wave oversensing in a cardiac system |
US11135441B2 (en) | 2016-06-08 | 2021-10-05 | Medtronic, Inc. | System and method for identifying and responding to P-wave oversensing in a cardiac system |
US10328274B2 (en) | 2016-06-08 | 2019-06-25 | Medtronic, Inc. | System and method for identifying and responding to P-wave oversensing in a cardiac system |
EP4201476A1 (en) | 2016-06-08 | 2023-06-28 | Medtronic, Inc. | System for identifying and responding to p-wave oversensing in a cardiac system |
WO2017213952A1 (en) | 2016-06-08 | 2017-12-14 | Medtronic, Inc. | System and method for identifying and responding to p-wave oversensing in a cardiac system |
US10512784B2 (en) | 2016-06-27 | 2019-12-24 | Cardiac Pacemakers, Inc. | Cardiac therapy system using subcutaneously sensed P-waves for resynchronization pacing management |
US11497921B2 (en) | 2016-06-27 | 2022-11-15 | Cardiac Pacemakers, Inc. | Cardiac therapy system using subcutaneously sensed p-waves for resynchronization pacing management |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US10426962B2 (en) | 2016-07-07 | 2019-10-01 | Cardiac Pacemakers, Inc. | Leadless pacemaker using pressure measurements for pacing capture verification |
US10688304B2 (en) | 2016-07-20 | 2020-06-23 | Cardiac Pacemakers, Inc. | Method and system for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US11134881B2 (en) | 2016-07-27 | 2021-10-05 | Medtronic, Inc. | Automatic thresholds for atrial tachyarrhythmia detection in an implantable medical device |
US10368769B2 (en) | 2016-07-27 | 2019-08-06 | Medtronic, Inc. | Automatic thresholds for atrial tachyarrhythmia detection in an implantable medical device |
US10850113B2 (en) | 2016-07-27 | 2020-12-01 | Medtronic, Inc. | Cardiac electrical signal morphology and pattern-based T-wave oversensing rejection |
US12004863B2 (en) | 2016-07-27 | 2024-06-11 | Medtronic, Inc. | Cardiac electrical signal gross morphology-based noise detection for rejection of ventricular tachyarrhythmia detection |
WO2018022422A1 (en) | 2016-07-27 | 2018-02-01 | Medtronic, Inc. | Cardiac electrical signal noise detection for tachyarrhythmia episode rejection |
US11654291B2 (en) | 2016-07-27 | 2023-05-23 | Medtronic, Inc. | Cardiac electrical signal morphology and pattern-based T-wave oversensing rejection |
WO2018022681A1 (en) | 2016-07-27 | 2018-02-01 | Medtronic, Inc. | Cardiac electrical signal gross morphology-based noise detection for rejection of ventricular tachyarrhythmia detection |
US10561332B2 (en) | 2016-07-27 | 2020-02-18 | Medtronic, Inc. | Cardiac electrical signal gross morphology-based noise detection for rejection of ventricular tachyarrhythmia detection |
WO2018022676A1 (en) | 2016-07-27 | 2018-02-01 | Medtronic, Inc. | Cardiac electrical signal morphology and pattern-based t-wave oversensing rejection |
EP3925663A1 (en) | 2016-07-27 | 2021-12-22 | Medtronic, Inc. | Cardiac electrical signal gross morphology-based noise detection for rejection of ventricular tachyarrhythmia detection |
US11337636B2 (en) | 2016-07-27 | 2022-05-24 | Medtronic, Inc. | Cardiac electrical signal gross morphology-based noise detection for rejection of ventricular tachyarrhythmia detection |
US10470681B2 (en) | 2016-07-27 | 2019-11-12 | Medtronic, Inc. | Cardiac electrical signal noise detection for tachyarrhythmia episode rejection |
US9999775B2 (en) | 2016-07-29 | 2018-06-19 | Medtronic, Inc. | System and method for controlling cardiac pacing mode switching |
WO2018022861A1 (en) | 2016-07-29 | 2018-02-01 | Medtronic, Inc. | System and method for controlling cardiac pacing mode switching |
US10391319B2 (en) | 2016-08-19 | 2019-08-27 | Cardiac Pacemakers, Inc. | Trans septal implantable medical device |
US10870008B2 (en) | 2016-08-24 | 2020-12-22 | Cardiac Pacemakers, Inc. | Cardiac resynchronization using fusion promotion for timing management |
US10780278B2 (en) | 2016-08-24 | 2020-09-22 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using P-wave to pace timing |
US11464982B2 (en) | 2016-08-24 | 2022-10-11 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using p-wave to pace timing |
US10758737B2 (en) | 2016-09-21 | 2020-09-01 | Cardiac Pacemakers, Inc. | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter |
US10905889B2 (en) | 2016-09-21 | 2021-02-02 | Cardiac Pacemakers, Inc. | Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery |
US10994145B2 (en) | 2016-09-21 | 2021-05-04 | Cardiac Pacemakers, Inc. | Implantable cardiac monitor |
US10463305B2 (en) | 2016-10-27 | 2019-11-05 | Cardiac Pacemakers, Inc. | Multi-device cardiac resynchronization therapy with timing enhancements |
US10413733B2 (en) | 2016-10-27 | 2019-09-17 | Cardiac Pacemakers, Inc. | Implantable medical device with gyroscope |
US10561330B2 (en) | 2016-10-27 | 2020-02-18 | Cardiac Pacemakers, Inc. | Implantable medical device having a sense channel with performance adjustment |
US10434314B2 (en) | 2016-10-27 | 2019-10-08 | Cardiac Pacemakers, Inc. | Use of a separate device in managing the pace pulse energy of a cardiac pacemaker |
US10758724B2 (en) | 2016-10-27 | 2020-09-01 | Cardiac Pacemakers, Inc. | Implantable medical device delivery system with integrated sensor |
US10765871B2 (en) | 2016-10-27 | 2020-09-08 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
US11305125B2 (en) | 2016-10-27 | 2022-04-19 | Cardiac Pacemakers, Inc. | Implantable medical device with gyroscope |
US10434317B2 (en) | 2016-10-31 | 2019-10-08 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
US10617874B2 (en) | 2016-10-31 | 2020-04-14 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
US10583301B2 (en) | 2016-11-08 | 2020-03-10 | Cardiac Pacemakers, Inc. | Implantable medical device for atrial deployment |
US10632313B2 (en) | 2016-11-09 | 2020-04-28 | Cardiac Pacemakers, Inc. | Systems, devices, and methods for setting cardiac pacing pulse parameters for a cardiac pacing device |
US10881869B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Wireless re-charge of an implantable medical device |
US10894163B2 (en) | 2016-11-21 | 2021-01-19 | Cardiac Pacemakers, Inc. | LCP based predictive timing for cardiac resynchronization |
US10881863B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker with multimode communication |
US11147979B2 (en) | 2016-11-21 | 2021-10-19 | Cardiac Pacemakers, Inc. | Implantable medical device with a magnetically permeable housing and an inductive coil disposed about the housing |
US10639486B2 (en) | 2016-11-21 | 2020-05-05 | Cardiac Pacemakers, Inc. | Implantable medical device with recharge coil |
US11207532B2 (en) | 2017-01-04 | 2021-12-28 | Cardiac Pacemakers, Inc. | Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system |
US10610694B2 (en) | 2017-01-20 | 2020-04-07 | Medtronic, Inc. | Implanted electrode configuration for physiological sensing and tissue conductance communication |
WO2018140343A1 (en) | 2017-01-26 | 2018-08-02 | Medtronic, Inc. | Detection of electromagnetic interference in a cardiac electrical signal by an implantable medical device |
US10835753B2 (en) | 2017-01-26 | 2020-11-17 | Cardiac Pacemakers, Inc. | Intra-body device communication with redundant message transmission |
US10029107B1 (en) | 2017-01-26 | 2018-07-24 | Cardiac Pacemakers, Inc. | Leadless device with overmolded components |
US10737102B2 (en) | 2017-01-26 | 2020-08-11 | Cardiac Pacemakers, Inc. | Leadless implantable device with detachable fixation |
US11590353B2 (en) | 2017-01-26 | 2023-02-28 | Cardiac Pacemakers, Inc. | Intra-body device communication with redundant message transmission |
US10583306B2 (en) | 2017-01-26 | 2020-03-10 | Medtronic, Inc. | Detection of electromagnetic interference in a cardiac electrical signal by an implantable medical device |
US10406373B2 (en) | 2017-01-26 | 2019-09-10 | Medtronic, Inc. | Noise detection and frequency determination in an extra-cardiovascular implantable cardioverter defibrillator system |
WO2018140336A1 (en) | 2017-01-26 | 2018-08-02 | Medtronic, Inc. | Noise detection and frequency determination in an extra-cardiovascular implantable cardioverter defibrillator system |
WO2018144665A1 (en) | 2017-02-06 | 2018-08-09 | Medtronic, Inc. | Charge balanced cardiac pacing from high voltage circuitry of an extra-cardiovascular implantable cardioverter defibrillator system |
US11524169B2 (en) | 2017-02-06 | 2022-12-13 | Medtronic, Inc. | Charge balanced cardiac pacing from high voltage circuitry of an extra-cardiovascular implantable cardioverter defibrillator system |
US12005263B2 (en) | 2017-02-06 | 2024-06-11 | Medtronic, Inc. | Charge balanced cardiac pacing from high voltage circuitry of an extra-cardiovascular implantable cardioverter defibrillator system |
US10391299B2 (en) | 2017-03-30 | 2019-08-27 | Medtronic, Inc. | Interventional medical systems for therapy delivery in extracardiovascular spaces and associated tools and methods |
US10905872B2 (en) | 2017-04-03 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device with a movable electrode biased toward an extended position |
US10821288B2 (en) | 2017-04-03 | 2020-11-03 | Cardiac Pacemakers, Inc. | Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate |
US10555684B2 (en) | 2017-04-25 | 2020-02-11 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
WO2018200228A1 (en) | 2017-04-25 | 2018-11-01 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
US12011278B2 (en) | 2017-04-25 | 2024-06-18 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
US10576288B2 (en) | 2017-04-26 | 2020-03-03 | Medtronic, Inc. | Cardiac event sensing in an implantable medical device |
US11357988B2 (en) | 2017-04-26 | 2022-06-14 | Medtronic, Inc. | Cardiac event sensing in an implantable medical device |
WO2018200227A1 (en) | 2017-04-26 | 2018-11-01 | Medtronic, Inc. | Cardiac event sensing in an implantable medical device |
US11638828B2 (en) | 2017-08-14 | 2023-05-02 | Medtronic, Inc. | Demand driven capacitor charging for cardiac pacing |
WO2019036266A1 (en) | 2017-08-14 | 2019-02-21 | Medtronic, Inc. | Demand driven capacitor charging for cardiac pacing |
US10751541B2 (en) | 2017-08-14 | 2020-08-25 | Medtronic, Inc. | Demand driven capacitor charging for cardiac pacing |
WO2019036258A1 (en) | 2017-08-15 | 2019-02-21 | Medtronic, Inc. | Anti-tachycardia pacing control in an implantable medical device system |
US11666763B2 (en) | 2017-08-15 | 2023-06-06 | Medtronic, Inc. | Anti-tachycardia pacing control in an implantable medical device system |
US10675471B2 (en) | 2017-08-15 | 2020-06-09 | Medtronic, Inc. | Anti-tachycardia pacing control in an implantable medical device system |
US11065459B2 (en) | 2017-08-18 | 2021-07-20 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
US10918875B2 (en) | 2017-08-18 | 2021-02-16 | Cardiac Pacemakers, Inc. | Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator |
US11235163B2 (en) | 2017-09-20 | 2022-02-01 | Cardiac Pacemakers, Inc. | Implantable medical device with multiple modes of operation |
US11547864B2 (en) | 2017-10-23 | 2023-01-10 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an implantable medical device |
EP4205802A1 (en) | 2017-10-23 | 2023-07-05 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an implantable medical device |
WO2019083911A1 (en) | 2017-10-23 | 2019-05-02 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an implantable medical device |
US10799710B2 (en) | 2017-10-23 | 2020-10-13 | Medtronic, Inc. | Multi-threshold sensing of cardiac electrical signals in an implantable medical device |
US11185703B2 (en) | 2017-11-07 | 2021-11-30 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker for bundle of his pacing |
WO2019108787A1 (en) | 2017-11-29 | 2019-06-06 | Medtronic, Inc. | Tissue conduction communication between devices |
US11045654B2 (en) | 2017-11-29 | 2021-06-29 | Medtronic, Inc. | Tissue conduction communication using ramped drive signal |
US11110279B2 (en) | 2017-11-29 | 2021-09-07 | Medtronic, Inc. | Signal transmission optimization for tissue conduction communication |
WO2019108765A1 (en) | 2017-11-29 | 2019-06-06 | Medtronic, Inc. | Tissue conduction communication using ramped drive signal |
US11213684B2 (en) | 2017-11-29 | 2022-01-04 | Medtronic, Inc. | Device and method to reduce artifact from tissue conduction communication transmission |
WO2019108742A1 (en) | 2017-11-29 | 2019-06-06 | Medtronic, Inc. | Device and method to reduce artifact from tissue conduction communication transmission |
US11660455B2 (en) | 2017-11-29 | 2023-05-30 | Medtronic, Inc. | Tissue conduction communication using ramped drive signal |
US11235162B2 (en) | 2017-11-29 | 2022-02-01 | Medtronic, Inc. | Tissue conduction communication between devices |
US11260216B2 (en) | 2017-12-01 | 2022-03-01 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker |
US11052258B2 (en) | 2017-12-01 | 2021-07-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker |
US11071870B2 (en) | 2017-12-01 | 2021-07-27 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker |
US11813463B2 (en) | 2017-12-01 | 2023-11-14 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker with reversionary behavior |
US11116981B2 (en) | 2017-12-15 | 2021-09-14 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
WO2019118807A1 (en) | 2017-12-15 | 2019-06-20 | Medtronic, Inc. | Device, system and method with adaptive timing for tissue conduction communication transmission |
US12011598B2 (en) | 2017-12-15 | 2024-06-18 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
EP3974023A1 (en) | 2017-12-15 | 2022-03-30 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
WO2019118560A1 (en) | 2017-12-15 | 2019-06-20 | Medtronic, Inc. | Supraventricular tachyarrhythmia discrimination |
US11229796B2 (en) | 2017-12-15 | 2022-01-25 | Medtronic Inc. | Device, system and method with adaptive timing for tissue conduction communication transmission |
US11529523B2 (en) | 2018-01-04 | 2022-12-20 | Cardiac Pacemakers, Inc. | Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone |
US10874861B2 (en) | 2018-01-04 | 2020-12-29 | Cardiac Pacemakers, Inc. | Dual chamber pacing without beat-to-beat communication |
US11213670B2 (en) | 2018-03-09 | 2022-01-04 | Medtronic, Inc. | Ventricular assist device and cardiac electrical stimulation system for therapy control |
WO2019173739A1 (en) | 2018-03-09 | 2019-09-12 | Medtronic, Inc. | Ventricular assist device and cardiac electrical stimulation system for therapy control |
US11235159B2 (en) | 2018-03-23 | 2022-02-01 | Medtronic, Inc. | VFA cardiac resynchronization therapy |
US11819699B2 (en) | 2018-03-23 | 2023-11-21 | Medtronic, Inc. | VfA cardiac resynchronization therapy |
US11058880B2 (en) | 2018-03-23 | 2021-07-13 | Medtronic, Inc. | VFA cardiac therapy for tachycardia |
US11400296B2 (en) | 2018-03-23 | 2022-08-02 | Medtronic, Inc. | AV synchronous VfA cardiac therapy |
WO2019195425A1 (en) | 2018-04-03 | 2019-10-10 | Medtronic, Inc. | Feature based sensing for leadless pacing therapy |
US10596383B2 (en) | 2018-04-03 | 2020-03-24 | Medtronic, Inc. | Feature based sensing for leadless pacing therapy |
US10765876B2 (en) | 2018-04-27 | 2020-09-08 | Medtronic, Inc. | Method and apparatus for delivering anti-tachycardia pacing |
WO2019210045A1 (en) | 2018-04-27 | 2019-10-31 | Medtronic, Inc. | Apparatus for charge balancing during delivery of electrical stimulation |
US11464992B2 (en) | 2018-04-27 | 2022-10-11 | Medtronic, Inc. | Method and apparatus for delivering anti-tachycardia pacing |
US11369795B2 (en) | 2018-04-27 | 2022-06-28 | Medtronic, Inc. | Method and apparatus for charge balancing during delivery of electrical stimulation |
WO2019209541A1 (en) | 2018-04-27 | 2019-10-31 | Medtronic, Inc. | Method and apparatus for delivering anti-tachycardia pacing |
US11071865B2 (en) | 2018-05-03 | 2021-07-27 | Medtronic, Inc. | Mode of operation for an implantable cardiac rhythm management device co-implanted with a ventricular assist device |
WO2019213190A1 (en) | 2018-05-03 | 2019-11-07 | Medtronic, Inc. | Mode of operation for an implantable cardiac rhythm management device co-implanted with a ventricular assist device |
US11298547B2 (en) | 2018-07-27 | 2022-04-12 | Medtronic, Inc. | Fluid status detection from a cardiac electrical signal and impedance signal |
WO2020023839A1 (en) | 2018-07-27 | 2020-01-30 | Medtronic, Inc. | Fluid status detection from a cardiac electrical signal and an impedance signal |
US11197687B2 (en) | 2018-08-01 | 2021-12-14 | Medtronic, Inc. | Medical tools for and methods of gaining access to extra vascular spaces |
WO2020028458A1 (en) | 2018-08-01 | 2020-02-06 | Medtronic, Inc. | Medical tools for and methods of gaining access to extravascular spaces |
US11235161B2 (en) | 2018-09-26 | 2022-02-01 | Medtronic, Inc. | Capture in ventricle-from-atrium cardiac therapy |
US11951313B2 (en) | 2018-11-17 | 2024-04-09 | Medtronic, Inc. | VFA delivery systems and methods |
US11679265B2 (en) | 2019-02-14 | 2023-06-20 | Medtronic, Inc. | Lead-in-lead systems and methods for cardiac therapy |
US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
US11213676B2 (en) | 2019-04-01 | 2022-01-04 | Medtronic, Inc. | Delivery systems for VfA cardiac therapy |
US11712188B2 (en) | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
US11305127B2 (en) | 2019-08-26 | 2022-04-19 | Medtronic Inc. | VfA delivery and implant region detection |
US11813466B2 (en) | 2020-01-27 | 2023-11-14 | Medtronic, Inc. | Atrioventricular nodal stimulation |
US11911168B2 (en) | 2020-04-03 | 2024-02-27 | Medtronic, Inc. | Cardiac conduction system therapy benefit determination |
US11813464B2 (en) | 2020-07-31 | 2023-11-14 | Medtronic, Inc. | Cardiac conduction system evaluation |
US12097377B2 (en) | 2021-03-09 | 2024-09-24 | Medtronic, Inc. | Asystole detection and response in an implantable cardioverter defibrillator |
Also Published As
Publication number | Publication date |
---|---|
US10137295B2 (en) | 2018-11-27 |
US12083333B2 (en) | 2024-09-10 |
EP3134169A1 (en) | 2017-03-01 |
US20190091467A1 (en) | 2019-03-28 |
US10661073B2 (en) | 2020-05-26 |
CN106413809A (en) | 2017-02-15 |
US20230310840A1 (en) | 2023-10-05 |
US11534603B2 (en) | 2022-12-27 |
US20180117303A1 (en) | 2018-05-03 |
US20150306410A1 (en) | 2015-10-29 |
CN106413809B (en) | 2019-09-17 |
US9855414B2 (en) | 2018-01-02 |
EP3134169B1 (en) | 2023-03-29 |
US20200282203A1 (en) | 2020-09-10 |
EP4223357B1 (en) | 2024-04-17 |
US20230109342A1 (en) | 2023-04-06 |
WO2015164715A1 (en) | 2015-10-29 |
EP4223357A1 (en) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12083333B2 (en) | Implantable extravascular electrical stimulation lead having improved sensing and pacing capability | |
US11344737B2 (en) | Implantable cardioverter-defibrillator (ICD) system including substernal lead | |
US11857779B2 (en) | Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead | |
US11524157B2 (en) | Substernal leadless electrical stimulation system | |
US10525272B2 (en) | Implantable medical device system having implantable cardioverter-defibrillator (ICD) system and substernal leadless pacing device | |
US9636512B2 (en) | Implantable cardioverter-defibrillator (ICD) system having multiple common polarity extravascular defibrillation electrodes | |
US10058695B2 (en) | Collapsible extravascular lead |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARSHALL, MARK T.;CAO, JIAN;CHRISTIE, MELISSA G.T.;AND OTHERS;SIGNING DATES FROM 20141021 TO 20141118;REEL/FRAME:034215/0205 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |